Tpl-2	B-protein
induces	O
IL-2	B-protein
expression	O
in	O
T-cell	B-cell_line
lines	I-cell_line
by	O
triggering	O
multiple	O
signaling	O
pathways	O
that	O
activate	O
NFAT	B-protein
and	O
NF-kappaB	B-protein
.	O

The	O
Tpl-2	B-protein
kinase	I-protein
activates	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
and	O
induces	O
IL-2	B-protein
expression	O
in	O
T-cell	B-cell_line
lines	I-cell_line
.	O

Here	O
we	O
show	O
that	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
by	O
Tpl-2	B-protein
is	O
inhibited	O
by	O
mutant	B-protein
signaling	I-protein
molecules	I-protein
that	O
inhibit	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
or	O
the	O
calcineurin	B-protein
/NFAT	B-protein
pathways	O
and	O
is	O
promoted	O
by	O
combinations	O
of	O
signaling	B-protein
molecules	I-protein
that	O
activate	O
these	O
pathways	O
.	O

We	O
,	O
therefore	O
,	O
conclude	O
that	O
signals	O
generated	O
by	O
the	O
convergence	O
of	O
the	O
MAPK	B-protein
and	O
the	O
calcineurin	B-protein
/NFAT	B-protein
pathway	O
are	O
necessary	O
and	O
sufficient	O
for	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
by	O
Tpl-2	B-protein
.	O

The	O
activation	O
of	O
both	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
an	O
NFAT-driven	B-DNA
minimal	I-DNA
promoter	I-DNA
were	O
shown	O
to	O
depend	O
on	O
signals	O
transduced	O
by	O
Raf1	B-protein
.	O

However	O
,	O
it	O
was	O
only	O
the	O
IL-2	B-DNA
promoter	I-DNA
whose	O
activation	O
by	O
Tpl-2	B-protein
was	O
fully	O
blocked	O
by	O
the	O
dominant	B-protein
negative	I-protein
mutant	I-protein
MEK1S218/222A	I-protein
and	O
the	O
MEK1/MEK2	O
inhibitor	O
PD098059	O
.	O

Since	O
the	O
activation	O
of	O
NFAT	B-protein
is	O
MAPK	B-protein
-dependent	O
these	O
findings	O
suggested	O
that	O
the	O
activation	O
of	O
MAPK	B-protein
by	O
Tpl-2	B-protein
is	O
either	O
independent	O
or	O
only	O
partially	O
dependent	O
on	O
MEK1	B-protein
and	O
MEK2	B-protein
.	O

In	O
addition	O
,	O
they	O
suggested	O
that	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
is	O
under	O
the	O
control	O
of	O
not	O
only	O
NFAT	B-protein
but	O
also	O
a	O
second	O
factor	O
whose	O
activation	O
is	O
MEK	B-protein
-dependent	O
.	O

Experiments	O
in	O
COS-1	B-cell_line
and	O
EL-4	B-cell_line
cells	I-cell_line
confirmed	O
both	O
hypotheses	O
and	O
revealed	O
that	O
the	O
second	O
factor	O
activated	O
by	O
Tpl-2	B-protein
is	O
NF-kappaB	B-protein
.	O

While	O
the	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
an	O
NFAT-driven	B-DNA
minimal	I-DNA
promoter	I-DNA
by	O
Tpl-2	B-protein
was	O
fully	O
blocked	O
by	O
the	O
dominant	B-protein
negative	I-protein
mutant	I-protein
NFAT	B-protein
delta418	I-protein
,	O
it	O
was	O
only	O
partially	O
blocked	O
by	O
the	O
calcineurin	B-protein
inhibitor	O
cyclosporin	O
A	O
suggesting	O
that	O
the	O
Tpl-2	B-protein
-mediated	O
NFAT	B-protein
activation	O
is	O
under	O
the	O
control	O
of	O
a	O
combination	O
of	O
calcineurin-dependent	O
and	O
independent	O
pathways	O
.	O

Both	O
pathways	O
were	O
fully	O
blocked	O
by	O
Bcl-2	B-protein
or	O
Bcl-X	B-protein
(	I-protein
L	I-protein
)	I-protein
.	O

Oncogene	NULL
(	NULL
1998	NULL
)	NULL
17	NULL
,	NULL
2609-2618	NULL
©	NULL
1998	NULL
Stockton	NULL
Press	NULL
All	NULL
rights	NULL
reserved	NULL
0950-9232/99	NULL
$	NULL
12.00	NULL
http	NULL
:	NULL
//www	NULL
.	NULL

stockton-press.co.uk/onc	NULL
Tpl-2	NULL
induces	NULL
IL-2	NULL
expression	NULL
in	NULL
T-cell	NULL
lines	NULL
by	NULL
triggering	NULL
multiple	NULL
signaling	NULL
pathways	NULL
that	NULL
activate	NULL
NFAT	NULL
and	NULL
NF-xB	NULL
Christos	NULL
Tsatsanis	NULL
'	NULL
,	NULL
Christos	NULL
and	NULL
Philip	NULL
N	NULL
Tsichlis	NULL
'	NULL
'Department	NULL
of	NULL
Microbiology	NULL
and	NULL
Immunology	NULL
,	NULL
Kimmel	NULL
Cancer	NULL
Center	NULL
,	NULL
Thomas	NULL
Jefferson	NULL
University	NULL
,	NULL
Philadelphia	NULL
,	NULL
Pennsylvania	NULL
19107	NULL
,	NULL
USA	NULL
The	NULL
Tpl-2	NULL
kinase	NULL
activates	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFAT	NULL
)	NULL
and	NULL
induces	NULL
IL-2	NULL
expression	NULL
in	NULL
T-cell	NULL
lines	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
Tpl-2	NULL
is	NULL
inhibited	NULL
by	NULL
mutant	NULL
signaling	NULL
molecules	NULL
that	NULL
inhibit	NULL
the	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
(	NULL
MAPK	NULL
)	NULL
or	NULL
the	NULL
calcineurin/NFAT	NULL
pathways	NULL
and	NULL
is	NULL
promoted	NULL
by	NULL
combinations	NULL
of	NULL
signaling	NULL
molecules	NULL
that	NULL
activate	NULL
these	NULL
pathways	NULL
.	NULL

We	NULL
,	NULL
therefore	NULL
,	NULL
conclude	NULL
that	NULL
signals	NULL
generated	NULL
by	NULL
the	NULL
convergence	NULL
of	NULL
the	NULL
MAPK	NULL
and	NULL
the	NULL
calcineurin/NFAT	NULL
pathway	NULL
are	NULL
necessary	NULL
and	NULL
sufficient	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
Tpl-2	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
both	NULL
the	NULL
IL-2	NULL
promoter	NULL
and	NULL
an	NULL
NFAT-driven	NULL
minimal	NULL
promoter	NULL
were	NULL
shown	NULL
to	NULL
depend	NULL
on	NULL
signals	NULL
transduced	NULL
by	NULL
Rafl	NULL
.	NULL

However	NULL
,	NULL
it	NULL
was	NULL
only	NULL
the	NULL
IL-2	NULL
promoter	NULL
whose	NULL
activation	NULL
by	NULL
Tpl-2	NULL
was	NULL
fully	NULL
blocked	NULL
by	NULL
the	NULL
dominant	NULL
negative	NULL
mutant	NULL
MEK1S218/	NULL
222A	NULL
and	NULL
the	NULL
MEK1/MEK2	NULL
inhibitor	NULL
PDO098059	NULL
.	NULL

Since	NULL
the	NULL
activation	NULL
of	NULL
NFAT	NULL
is	NULL
MAPK-dependent	NULL
these	NULL
findings	NULL
suggested	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
MAPK	NULL
by	NULL
Tpl-2	NULL
is	NULL
either	NULL
independent	NULL
or	NULL
only	NULL
partially	NULL
dependent	NULL
on	NULL
MEK1	NULL
and	NULL
MEK2	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
they	NULL
suggested	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
is	NULL
under	NULL
the	NULL
control	NULL
of	NULL
not	NULL
only	NULL
NFAT	NULL
but	NULL
also	NULL
a	NULL
second	NULL
factor	NULL
whose	NULL
activation	NULL
is	NULL
MEK-dependent	NULL
.	NULL

Experiments	NULL
in	NULL
COS-1	NULL
and	NULL
EL-4	NULL
cells	NULL
confirmed	NULL
both	NULL
hypotheses	NULL
and	NULL
revealed	NULL
that	NULL
the	NULL
second	NULL
factor	NULL
activated	NULL
by	NULL
Tpl-2	NULL
is	NULL
NF-xB	NULL
.	NULL

While	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
and	NULL
an	NULL
NFAT-driven	NULL
minimal	NULL
promoter	NULL
by	NULL
Tpl-2	NULL
was	NULL
fully	NULL
blocked	NULL
by	NULL
the	NULL
dominant	NULL
negative	NULL
mutant	NULL
NFATA4I8	NULL
,	NULL
it	NULL
was	NULL
only	NULL
partially	NULL
blocked	NULL
by	NULL
the	NULL
calcineurin	NULL
inhibitor	NULL
cyclosporin	NULL
A	NULL
suggesting	NULL
that	NULL
the	NULL
Tpl-2-mediated	NULL
NFAT	NULL
activation	NULL
is	NULL
under	NULL
the	NULL
control	NULL
of	NULL
a	NULL
combination	NULL
of	NULL
calcineurin-dependent	NULL
and	NULL
independent	NULL
pathways	NULL
.	NULL

Both	NULL
pathways	NULL
were	NULL
fully	NULL
blocked	NULL
by	NULL
Bel-2	NULL
or	NULL
Bcl-X	NULL
,	NULL
.	NULL

Keywords	NULL
:	NULL
Tpl-2	NULL
;	NULL
NF	NULL
kappa	NULL
B	NULL
;	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
;	NULL
interleukin	NULL
2	NULL
Introduction	NULL
Activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
depends	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
several	NULL
obligatory	NULL
transcription	NULL
factors	NULL
including	NULL
NFAT	NULL
and	NULL
NF-KB	NULL
.	NULL

NFAT	NULL
is	NULL
a	NULL
complex	NULL
factor	NULL
composed	NULL
of	NULL
API	NULL
and	NULL
Correspondence	NULL
:	NULL
PN	NULL
Tsichlis	NULL
,	NULL
Department	NULL
of	NULL
Microbiology	NULL
and	NULL
Immunology	NULL
,	NULL
Kimmel	NULL
Cancer	NULL
Center	NULL
,	NULL
Thomas	NULL
Jefferson	NULL
University	NULL
,	NULL
Philadelphia	NULL
,	NULL
PA	NULL
19107	NULL
,	NULL
USA	NULL
Present	NULL
address	NULL
:	NULL
Fox	NULL
Chase	NULL
Cancer	NULL
Center	NULL
,	NULL
7701	NULL
Burholme	NULL
Avenue	NULL
,	NULL
Philadelphia	NULL
,	NULL
PA	NULL
19111	NULL
,	NULL
USA	NULL
Received	NULL
10	NULL
July	NULL
1998	NULL
;	NULL
revised	NULL
18	NULL
September	NULL
1998	NULL
;	NULL
accepted	NULL
29	NULL
September	NULL
1998	NULL
NFAT	NULL
components	NULL
(	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Northrop	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

The	NULL
NFAT	NULL
component	NULL
is	NULL
heterogeneous	NULL
and	NULL
is	NULL
represented	NULL
by	NULL
at	NULL
least	NULL
four	NULL
protein	NULL
isoforms	NULL
encoded	NULL
by	NULL
different	NULL
genes	NULL
that	NULL
are	NULL
differentially	NULL
expressed	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
types	NULL
.	NULL

These	NULL
are	NULL
NFATe	NULL
(	NULL
NFATel	NULL
or	NULL
NFAT2	NULL
)	NULL
,	NULL
NFATp	NULL
(	NULL
NFATc2	NULL
or	NULL
NFATI1	NULL
)	NULL
,	NULL
NFAT3	NULL
and	NULL
NFATx	NULL
(	NULL
NFATc3	NULL
or	NULL
NFAT4	NULL
)	NULL
(	NULL
Rao	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Activation	NULL
and	NULL
nuclear	NULL
translocation	NULL
of	NULL
NFAT	NULL
is	NULL
regulated	NULL
by	NULL
phosphorylation	NULL
.	NULL

This	NULL
is	NULL
under	NULL
the	NULL
control	NULL
of	NULL
several	NULL
serine	NULL
threonine	NULL
protein	NULL
kinases	NULL
including	NULL
GSK3	NULL
and	NULL
JNK2	NULL
and	NULL
phosphatases	NULL
including	NULL
calcineurin	NULL
(	NULL
Shibasaki	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Chow	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
;	NULL
Rao	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
and	NULL
FK	NULL
506	NULL
,	NULL
two	NULL
immunosuppressive	NULL
drugs	NULL
that	NULL
inhibit	NULL
NFAT	NULL
activation	NULL
,	NULL
act	NULL
by	NULL
blocking	NULL
the	NULL
activation	NULL
of	NULL
calcineurin	NULL
and	NULL
the	NULL
depho-sphorylation	NULL
of	NULL
NFAT	NULL
(	NULL
Schreiber	NULL
and	NULL
Crabtree	NULL
,	NULL
1992	NULL
;	NULL
Clipstone	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Clipstone	NULL
and	NULL
Crabtree	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

Tpl-2	NULL
,	NULL
an	NULL
oncogenic	NULL
serine-threonine	NULL
protein	NULL
kinase	NULL
(	NULL
Patriotis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Ceci	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
that	NULL
is	NULL
the	NULL
subject	NULL
of	NULL
this	NULL
report	NULL
,	NULL
transduces	NULL
signals	NULL
that	NULL
promote	NULL
NFAT	NULL
p	NULL
activation	NULL
perhaps	NULL
by	NULL
inducing	NULL
dephosphoryla-tion	NULL
of	NULL
the	NULL
protein	NULL
(	NULL
Tsatsanis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

NFAT	NULL
isoforms	NULL
expressed	NULL
in	NULL
different	NULL
tissues	NULL
regulate	NULL
the	NULL
expression	NULL
of	NULL
cytokine	NULL
genes	NULL
.	NULL

In	NULL
the	NULL
hematopoietic	NULL
system	NULL
,	NULL
NFAT	NULL
contributes	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
several	NULL
cytokines	NULL
and	NULL
other	NULL
early	NULL
response	NULL
genes	NULL
including	NULL
IL-2	NULL
,	NULL
IL-3	NULL
,	NULL
IL-4	NULL
,	NULL
IL-5	NULL
,	NULL
IL-8	NULL
,	NULL
IL-13	NULL
,	NULL
GM-CSF	NULL
,	NULL
IFN-y	NULL
,	NULL
TNF-	NULL
«	NULL
,	NULL
CD40	NULL
ligand	NULL
and	NULL
Fas	NULL
ligand	NULL
(	NULL
Rao	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
its	NULL
role	NULL
in	NULL
cytokine	NULL
gene	NULL
expression	NULL
,	NULL
NFAT	NULL
interacts	NULL
directly	NULL
with	NULL
the	NULL
cell	NULL
cycle	NULL
and	NULL
apoptotic	NULL
machineries	NULL
.	NULL

Thus	NULL
,	NULL
activation	NULL
of	NULL
NFAT	NULL
promotes	NULL
both	NULL
the	NULL
progression	NULL
from	NULL
G1	NULL
to	NULL
S	NULL
as	NULL
well	NULL
as	NULL
apoptosis	NULL
.	NULL

Overexpressed	NULL
Bel-2	NULL
interacts	NULL
with	NULL
calcineurin	NULL
and	NULL
inhibits	NULL
NFAT	NULL
activation	NULL
(	NULL
Linette	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
,	NULL
while	NULL
overexpression	NULL
of	NULL
Bax	NULL
,	NULL
a	NULL
pro-apoptotic	NULL
member	NULL
of	NULL
the	NULL
Bcl-2	NULL
family	NULL
of	NULL
proteins	NULL
,	NULL
reverses	NULL
the	NULL
effect	NULL
of	NULL
Bel-2	NULL
by	NULL
blocking	NULL
its	NULL
interaction	NULL
with	NULL
calcineurin	NULL
(	NULL
Shibasaki	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
IL-2	NULL
expression	NULL
following	NULL
T	NULL
cell	NULL
stimulation	NULL
depends	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
not	NULL
only	NULL
NFAT	NULL
but	NULL
also	NULL
NF-xB	NULL
,	NULL
another	NULL
complex	NULL
transcription	NULL
factor	NULL
that	NULL
contributes	NULL
to	NULL
lymphocyte	NULL
activation	NULL
and	NULL
cytokine	NULL
gene	NULL
expression	NULL
(	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

NF-xB	NULL
represents	NULL
a	NULL
protein	NULL
family	NULL
whose	NULL
members	NULL
include	NULL
p65	NULL
(	NULL
ReIA	NULL
)	NULL
,	NULL
c-Rel	NULL
,	NULL
RelB	NULL
,	NULL
p50	NULL
(	NULL
NF-xB1l	NULL
)	NULL
and	NULL
p52	NULL
(	NULL
NF-xB2	NULL
)	NULL
.	NULL

Some	NULL
of	NULL
these	NULL
proteins	NULL
,	NULL
such	NULL
as	NULL
p50	NULL
and	NULL
p52	NULL
,	NULL
are	NULL
expressed	NULL
as	NULL
inactive	NULL
precursors	NULL
(	NULL
p105	NULL
and	NULL
p100	NULL
,	NULL
respectively	NULL
)	NULL
that	NULL
are	NULL
localized	NULL
primarily	NULL
in	NULL
the	NULL
cytosol	NULL
(	NULL
Thanos	NULL
and	NULL
Maniatis	NULL
,	NULL
1995	NULL
;	NULL
Baeuerle	NULL
and	NULL
Baltimore	NULL
,	NULL
1996	NULL
)	NULL
.	NULL

Potentially	NULL
active	NULL
NF-xB	NULL
proteins	NULL
are	NULL
also	NULL
localized	NULL
primarily	NULL
in	NULL
the	NULL
cytosol	NULL
bound	NULL
to	NULL
a	NULL
family	NULL
of	NULL
inhibitory	NULL
proteins	NULL
(	NULL
Ix-Ba	NULL
,	NULL
Ix-B	NULL
#	NULL
,	NULL
Ix-By	NULL
and	NULL
Ix-Be	NULL
)	NULL
(	NULL
Beg	NULL
and	NULL
Baldwin	NULL
,	NULL
1993	NULL
,	NULL
Simeonidis	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

NF-xB	NULL
activation	NULL
signals	NULL
induce	NULL
proteolytic	NULL
cleavage	NULL
of	NULL
the	NULL
Tpl-2	NULL
activates	NULL
NFAT	NULL
and	NULL
NF-xB	NULL
C	NULL
Tsatsanis	NULL
et	NULL
al	NULL
2610	NULL
precursor	NULL
proteins	NULL
or	NULL
lead	NULL
to	NULL
the	NULL
degradation	NULL
of	NULL
the	NULL
inhibitory	NULL
Ix-B	NULL
molecules	NULL
(	NULL
Chen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

The	NULL
released	NULL
active	NULL
NF-xB	NULL
molecules	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
and	NULL
bind	NULL
DNA	NULL
as	NULL
homodimers	NULL
or	NULL
heterodimers	NULL
(	NULL
Fujita	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

Tpl-2	NULL
is	NULL
a	NULL
serine-threonine	NULL
protein	NULL
kinase	NULL
that	NULL
is	NULL
activated	NULL
by	NULL
carboxy-terminal	NULL
truncation	NULL
during	NULL
progression	NULL
of	NULL
MoMuLV	NULL
induced	NULL
T	NULL
cell	NULL
lymphomas	NULL
and	NULL
MMTV-induced	NULL
mammary	NULL
carcinomas	NULL
(	NULL
Patriotis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Makris	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Ceci	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
;	NULL
Erny	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Earlier	NULL
studies	NULL
had	NULL
shown	NULL
that	NULL
Tpl-2	NULL
transduces	NULL
signals	NULL
that	NULL
activate	NULL
the	NULL
MAPKinase	NULL
and	NULL
the	NULL
SAPKinase	NULL
cascades	NULL
(	NULL
Ceci	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
;	NULL
Patriotis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Salmeron	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

More	NULL
recent	NULL
studies	NULL
revealed	NULL
that	NULL
Tpl-2	NULL
activates	NULL
NFAT	NULL
in	NULL
various	NULL
cell	NULL
types	NULL
(	NULL
Tsatsanis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
and	NULL
induces	NULL
IL-2	NULL
expression	NULL
when	NULL
transfected	NULL
in	NULL
EL4	NULL
and	NULL
Jurkat	NULL
cells	NULL
(	NULL
Ballester	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
;	NULL
Tsatsanis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

The	NULL
Tpl-2-dependent	NULL
pathway	NULL
leading	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
these	NULL
cell	NULL
lines	NULL
can	NULL
be	NULL
triggered	NULL
by	NULL
TCR	NULL
stimulation	NULL
(	NULL
Tsatsanis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

In	NULL
this	NULL
report	NULL
we	NULL
show	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
NFAT	NULL
and	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
Tpl-2	NULL
depends	NULL
on	NULL
the	NULL
convergence	NULL
of	NULL
calcineurin/NFAT	NULL
and	NULL
MAPK	NULL
activation	NULL
signals	NULL
induced	NULL
by	NULL
Tpl-2	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
NFAT	NULL
is	NULL
under	NULL
the	NULL
control	NULL
of	NULL
a	NULL
combination	NULL
of	NULL
calcineurin-dependent	NULL
and	NULL
calcineurin-independent	NULL
pathways	NULL
,	NULL
both	NULL
of	NULL
which	NULL
are	NULL
blocked	NULL
by	NULL
Bel-2	NULL
and	NULL
Bcel-X	NULL
,	NULL
..	NULL
Activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
but	NULL
not	NULL
of	NULL
the	NULL
NFAT	NULL
minimal	NULL
promoter	NULL
is	NULL
fully	NULL
blocked	NULL
by	NULL
inhibitors	NULL
of	NULL
MEK	NULL
1	NULL
and	NULL
MEK2	NULL
.	NULL

Evidence	NULL
presented	NULL
in	NULL
this	NULL
report	NULL
shows	NULL
that	NULL
the	NULL
difference	NULL
between	NULL
the	NULL
two	NULL
promoters	NULL
is	NULL
due	NULL
to	NULL
a	NULL
combination	NULL
of	NULL
factors	NULL
:	NULL
a	NULL
)	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
MAPK	NULL
by	NULL
Tpl-2	NULL
is	NULL
at	NULL
least	NULL
in	NULL
part	NULL
MEK1/MEK2	NULL
independent	NULL
and	NULL
b	NULL
)	NULL
Tpl-2	NULL
also	NULL
activates	NULL
NF-xB	NULL
,	NULL
another	NULL
transcription	NULL
factor	NULL
that	NULL
plays	NULL
an	NULL
obligatory	NULL
role	NULL
in	NULL
IL-2	NULL
induction	NULL
,	NULL
via	NULL
a	NULL
MEK1/MEK2	NULL
dependent	NULL
mechanism	NULL
.	NULL

Results	NULL
Dominant	NULL
negative	NULL
mutants	NULL
inhibiting	NULL
the	NULL
MAPK	NULL
and	NULL
the	NULL
calcineurin|NFAT	NULL
pathways	NULL
block	NULL
the	NULL
Tpl-2	NULL
mediated	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
We	NULL
had	NULL
previously	NULL
shown	NULL
that	NULL
Tpl-2	NULL
induces	NULL
IL-2	NULL
expression	NULL
in	NULL
EL4	NULL
and	NULL
Jurkat	NULL
cells	NULL
.	NULL

Moreover	NULL
,	NULL
we	NULL
had	NULL
shown	NULL
that	NULL
Tpl-2	NULL
activates	NULL
NFAT	NULL
,	NULL
a	NULL
complex	NULL
transcription	NULL
factor	NULL
composed	NULL
of	NULL
NFAT	NULL
and	NULL
API	NULL
components	NULL
,	NULL
whose	NULL
activation	NULL
is	NULL
obligatory	NULL
for	NULL
IL-2	NULL
induction	NULL
(	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Luo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Northrop	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Rooney	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Since	NULL
Tpl-2	NULL
activates	NULL
NFAT	NULL
as	NULL
well	NULL
as	NULL
the	NULL
MAPK	NULL
pathway	NULL
(	NULL
Ceci	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
;	NULL
Tsatsanis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
,	NULL
which	NULL
is	NULL
required	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
API	NULL
(	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
we	NULL
examined	NULL
whether	NULL
dominant	NULL
negative	NULL
mutants	NULL
of	NULL
several	NULL
proteins	NULL
transducing	NULL
signals	NULL
along	NULL
these	NULL
pathways	NULL
inhibit	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
Tpl-2	NULL
.	NULL

To	NULL
this	NULL
end	NULL
,	NULL
EL4	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
an	NULL
IL-2	NULL
promoter/	NULL
CAT	NULL
reporter	NULL
construct	NULL
,	NULL
a	NULL
Tpl-2	NULL
expression	NULL
construct	NULL
and	NULL
expression	NULL
constructs	NULL
of	NULL
the	NULL
dominant	NULL
negative	NULL
(	NULL
DN	NULL
)	NULL
mutants	NULL
Ha-ras	NULL
N17	NULL
,	NULL
MEK1S218/222A	NULL
,	NULL
RaflS621A	NULL
and	NULL
NFATcA418	NULL
.	NULL

The	NULL
results	NULL
showed	NULL
that	NULL
these	NULL
dominant	NULL
negative	NULL
mutants	NULL
block	NULL
the	NULL
Tpl-2	NULL
mediated	NULL
induction	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
and	NULL
suggested	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
Tpl-2	NULL
depends	NULL
on	NULL
the	NULL
convergence	NULL
of	NULL
the	NULL
MAPK	NULL
and	NULL
the	NULL
calcineurin/NFAT	NULL
pathways	NULL
.	NULL

Additional	NULL
experiments	NULL
in	NULL
the	NULL
following	NULL
two	NULL
paragraphs	NULL
provide	NULL
support	NULL
for	NULL
this	NULL
conclusion	NULL
.	NULL

Wild-type	NULL
Tpl-2	NULL
activates	NULL
the	NULL
IL-2	NULL
promoter	NULL
and	NULL
an	NULL
NFAT-driven	NULL
promoter	NULL
in	NULL
Jurkat	NULL
cells	NULL
only	NULL
when	NULL
co-expressed	NULL
with	NULL
activated	NULL
calcineurin	NULL
We	NULL
had	NULL
previously	NULL
shown	NULL
that	NULL
EL4	NULL
cells	NULL
express	NULL
IL-2	NULL
following	NULL
transfection	NULL
of	NULL
either	NULL
the	NULL
wild-type	NULL
or	NULL
the	NULL
oncogenic	NULL
carboxy-terminally	NULL
truncated	NULL
Tpl-2	NULL
constructs	NULL
(	NULL
Tsatsanis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
Jurkat	NULL
cells	NULL
express	NULL
IL-2	NULL
,	NULL
only	NULL
in	NULL
response	NULL
to	NULL
carboxy-terminally	NULL
truncated	NULL
Tpl-2	NULL
.	NULL

Since	NULL
EL4	NULL
cells	NULL
express	NULL
a	NULL
mutant	NULL
calcineurin	NULL
(	NULL
CnAD477N	NULL
)	NULL
which	NULL
is	NULL
more	NULL
sensitive	NULL
to	NULL
fluctuations	NULL
in	NULL
the	NULL
concentration	NULL
of	NULL
cytoplasmic	NULL
calcium	NULL
(	NULL
Fruman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
we	NULL
hypothesized	NULL
that	NULL
the	NULL
enhanced	NULL
sensitivity	NULL
of	NULL
EL4	NULL
cells	NULL
to	NULL
Tpl-2	NULL
may	NULL
be	NULL
due	NULL
to	NULL
the	NULL
partially	NULL
activated	NULL
calcineurin	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

To	NULL
test	NULL
this	NULL
hypothesis	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
wild-type	NULL
or	NULL
truncated	NULL
Tpl-2	NULL
constructs	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
the	NULL
activated	NULL
form	NULL
of	NULL
calcineurin	NULL
,	NULL
ACnA	NULL
,	NULL
and	NULL
the	NULL
expression	NULL
of	NULL
IL-2	NULL
was	NULL
monitored	NULL
using	NULL
an	NULL
ELISA	NULL
assay	NULL
(	NULL
Figure	NULL
2a	NULL
)	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
same	NULL
combinations	NULL
of	NULL
expression	NULL
constructs	NULL
were	NULL
cotransfected	NULL
with	NULL
the	NULL
IL-2/CAT	NULL
reporter	NULL
construct	NULL
and	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
was	NULL
monitored	NULL
by	NULL
measuring	NULL
CAT	NULL
enzy-matic	NULL
activity	NULL
in	NULL
transfected	NULL
cell	NULL
lysates	NULL
(	NULL
Figure	NULL
2b	NULL
,	NULL
samples	NULL
1-4	NULL
)	NULL
.	NULL

The	NULL
results	NULL
confirmed	NULL
the	NULL
proposed	NULL
hypothesis	NULL
by	NULL
showing	NULL
that	NULL
both	NULL
the	NULL
endogenous	NULL
IL-2	NULL
promoter	NULL
and	NULL
the	NULL
transiently	NULL
transfected	NULL
IL-2/CAT	NULL
reporter	NULL
were	NULL
activated	NULL
in	NULL
Jurkat	NULL
cells	NULL
cotransfected	NULL
with	NULL
expression	NULL
constructs	NULL
of	NULL
the	NULL
wild-type	NULL
Tpl-2	NULL
and	NULL
the	NULL
activated	NULL
calcineurin	NULL
but	NULL
not	NULL
wild-type	NULL
Tpl-2	NULL
alone	NULL
IL-2/CAT	NULL
3	NULL
50	NULL
Relative	NULL
CAT	NULL
activity	NULL
0	NULL
+94	NULL
Tpl-2	NULL
wt	NULL
PMA/iono	NULL
c-Ha-Ras	NULL
N17	NULL
Raf-1	NULL
S621A	NULL
MEK1	NULL
$	NULL
218/222A	NULL
SEK1	NULL
K299R	NULL
NFATe	NULL
A418	NULL
5	NULL
+	NULL
+	NULL
wa	NULL
a	NULL
a	NULL
a	NULL
a	NULL
a	NULL
3	NULL
+	NULL
+	NULL
roan	NULL
6	NULL
4a	NULL
14.sz	NULL
rog	NULL
6	NULL
a	NULL
t	NULL
4	NULL
®	NULL
go	NULL
6	NULL
6	NULL
b	NULL
0	NULL
|+\IE	NULL
8	NULL
+	NULL
Figure	NULL
1	NULL
Activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
Tpl-2	NULL
is	NULL
inhibited	NULL
by	NULL
dominant	NULL
inhibitory	NULL
mutants	NULL
of	NULL
the	NULL
MAPK	NULL
and	NULL
the	NULL
calcium/	NULL
calcineurin	NULL
NFAT	NULL
pathways	NULL
.	NULL

EL4	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
Tpl-2	NULL
,	NULL
the	NULL
IL-2/CAT	NULL
reporter	NULL
construct	NULL
and	NULL
the	NULL
indicated	NULL
constructs	NULL
of	NULL
dominant	NULL
negative	NULL
mutants	NULL
.	NULL

The	NULL
indicated	NULL
cultures	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
36	NULL
h	NULL
after	NULL
transfection	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
the	NULL
cell	NULL
lysates	NULL
and	NULL
was	NULL
quantitated	NULL
by	NULL
phospho-imager	NULL
.	NULL

Transfections	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
quadruplicate	NULL
and	NULL
expression	NULL
was	NULL
normalized	NULL
based	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
B-Gal	NULL
from	NULL
a	NULL
cotransfected	NULL
CMV5/	NULL
$	NULL
-Gal	NULL
construct	NULL
(	NULL
Figure	NULL
2b	NULL
,	NULL
samples	NULL
2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

Identical	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
,	NULL
instead	NULL
of	NULL
the	NULL
IL-2/CAT	NULL
construct	NULL
,	NULL
a	NULL
reporter	NULL
construct	NULL
utilizing	NULL
an	NULL
NFAT-driven	NULL
minimal	NULL
promoter	NULL
(	NULL
NFAT/CAT	NULL
)	NULL
was	NULL
used	NULL
(	NULL
Figure	NULL
2b	NULL
,	NULL
samples	NULL
5-8	NULL
)	NULL
.	NULL

The	NULL
combined	NULL
activation	NULL
of	NULL
the	NULL
MAPK	NULL
and	NULL
calcineurin/	NULL
NFAT	NULL
pathways	NULL
by	NULL
Raf1Y340D	NULL
and	NULL
NFATp	NULL
,	NULL
NFATe	NULL
or	NULL
ACnA	NULL
activates	NULL
the	NULL
NFAT-driven	NULL
minimal	NULL
promoter	NULL
Tpl-2	NULL
as	NULL
well	NULL
as	NULL
v-Ha-ras	NULL
activated	NULL
the	NULL
NFAT-driven	NULL
minimal	NULL
promoter	NULL
in	NULL
EL4	NULL
cells	NULL
while	NULL
RaflY340D	NULL
,	NULL
a	NULL
potent	NULL
activator	NULL
of	NULL
the	NULL
MAPK	NULL
pathway	NULL
as	NULL
well	NULL
as	NULL
the	NULL
IL-2	NULL
ELISA	NULL
assay	NULL
1250	NULL
1000	NULL
IL-2	NULL
750	NULL
pg/ml	NULL
500	NULL
250	NULL
0	NULL
Tpl-2	NULL
wt	NULL
Tpl2	NULL
tr	NULL
ACnA	NULL
PMA/iono	NULL
.	NULL

1004	NULL
_	NULL
_-	NULL
ps	NULL
oo	NULL
mp	NULL
Relative	NULL
CAT	NULL
activity	NULL
IL2	NULL
CAT	NULL
NFAT	NULL
CAT	NULL
Tpl2	NULL
A	NULL
CnA	NULL
PMA/iono	NULL
.	NULL

LJ	NULL
5	NULL
+	NULL
|||+._.E	NULL
E_l	NULL
6	NULL
+	NULL
+	NULL
.-+-+~I	NULL
3	NULL
+	NULL
+	NULL
=	NULL
+	NULL
-o	NULL
+	NULL
to	NULL
>	NULL
-	NULL
+	NULL
#	NULL
Figure	NULL
2	NULL
-	NULL
EL4	NULL
cells	NULL
are	NULL
more	NULL
sensitive	NULL
than	NULL
Jurkat	NULL
cells	NULL
to	NULL
Tpl-2-induced	NULL
activation	NULL
of	NULL
NFAT	NULL
and	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Role	NULL
of	NULL
calcineurin	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
wild-type	NULL
or	NULL
truncated	NULL
(	NULL
tr	NULL
)	NULL
Tpl-2	NULL
with	NULL
or	NULL
without	NULL
ACnA	NULL
.	NULL

Control	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
36	NULL
h	NULL
later	NULL
and	NULL
they	NULL
were	NULL
harvested	NULL
after	NULL
an	NULL
additional	NULL
8	NULL
h	NULL
period	NULL
.	NULL

IL-2	NULL
expression	NULL
was	NULL
measured	NULL
by	NULL
ELISA	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
the	NULL
IL-2/CAT	NULL
or	NULL
the	NULL
NFAT/CAT	NULL
reporter	NULL
construct	NULL
and	NULL
wild-type	NULL
Tpl-2	NULL
with	NULL
or	NULL
without	NULL
ACnA	NULL
or	NULL
NFATc	NULL
.	NULL

Control	NULL
cells	NULL
were	NULL
stimulated	NULL
36	NULL
h	NULL
later	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
at	NULL
44	NULL
h	NULL
following	NULL
transfection	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
the	NULL
cell	NULL
lysates	NULL
and	NULL
quantitated	NULL
by	NULL
phospho-imager	NULL
.	NULL

All	NULL
transfections	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
quadruplicate	NULL
and	NULL
expression	NULL
was	NULL
normalized	NULL
based	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
$	NULL
-Gal	NULL
from	NULL
a	NULL
cotransfected	NULL
CMV	NULL
construct	NULL
Tpl-2	NULL
activates	NULL
NFAT	NULL
and	NULL
NF-xB	NULL
C	NULL
Tsatsanis	NULL
et	NULL
al	NULL
activators	NULL
of	NULL
the	NULL
NFAT	NULL
pathway	NULL
NFAT	NULL
,	NULL
NFATp	NULL
,	NULL
NFATx	NULL
,	NULL
ACnA	NULL
and	NULL
CAML	NULL
failed	NULL
to	NULL
do	NULL
so	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
confirmed	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
neither	NULL
the	NULL
MAPK	NULL
nor	NULL
the	NULL
calcineurin/NFAT	NULL
pathway	NULL
alone	NULL
is	NULL
sufficient	NULL
to	NULL
activate	NULL
the	NULL
NFAT-driven	NULL
promoter	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
the	NULL
concerted	NULL
activation	NULL
of	NULL
the	NULL
two	NULL
pathways	NULL
activates	NULL
the	NULL
NFAT-driven	NULL
promoter	NULL
,	NULL
EL4	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
the	NULL
reporter	NULL
NFAT/CAT	NULL
construct	NULL
and	NULL
expression	NULL
constructs	NULL
of	NULL
Raf1	NULL
Y340D	NULL
and	NULL
each	NULL
of	NULL
the	NULL
listed	NULL
activators	NULL
of	NULL
the	NULL
NFAT	NULL
pathway	NULL
.	NULL

The	NULL
results	NULL
confirmed	NULL
that	NULL
the	NULL
synergistic	NULL
action	NULL
of	NULL
RaflY340D	NULL
and	NULL
NFATc	NULL
,	NULL
NFATp	NULL
or	NULL
ACn¥A	NULL
is	NULL
sufficient	NULL
to	NULL
activate	NULL
the	NULL
NFAT-driven	NULL
minimal	NULL
promoter	NULL
(	NULL
Figure	NULL
3	NULL
,	NULL
samples	NULL
4	NULL
,	NULL
6	NULL
and	NULL
12	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
activation	NULL
of	NULL
NFAT	NULL
by	NULL
Tpl-2	NULL
is	NULL
due	NULL
to	NULL
the	NULL
combined	NULL
activation	NULL
of	NULL
these	NULL
pathways	NULL
both	NULL
of	NULL
which	NULL
are	NULL
known	NULL
to	NULL
be	NULL
induced	NULL
by	NULL
Tpl-2	NULL
(	NULL
Tsatsanis	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

Cyclosporin	NULL
A	NULL
inhibits	NULL
partially	NULL
while	NULL
Bel-2	NULL
and	NULL
Bel-X	NULL
,	NULL
inhibit	NULL
fully	NULL
the	NULL
Tpl-2-mediated	NULL
activation	NULL
of	NULL
NFAT	NULL
CsA	NULL
is	NULL
an	NULL
immunosuppressant	NULL
that	NULL
inhibits	NULL
IL-2	NULL
expression	NULL
by	NULL
blocking	NULL
the	NULL
calcineurin-mediated	NULL
activation	NULL
of	NULL
NFAT	NULL
induced	NULL
by	NULL
phorbol	NULL
esters	NULL
and	NULL
ionomycin	NULL
.	NULL

Treatment	NULL
of	NULL
the	NULL
Tpl-2	NULL
transfected	NULL
EL4	NULL
cells	NULL
with	NULL
CsA	NULL
only	NULL
partially	NULL
blocked	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
and	NULL
the	NULL
NFAT-driven	NULL
minimal	NULL
promoter	NULL
(	NULL
Figure	NULL
4a	NULL
,	NULL
sample	NULL
3	NULL
and	NULL
Figure	NULL
4b	NULL
,	NULL
samples	NULL
7	NULL
and	NULL
9	NULL
)	NULL
.	NULL

This	NULL
finding	NULL
which	NULL
was	NULL
unexpected	NULL
given	NULL
the	NULL
profound	NULL
inhibition	NULL
of	NULL
both	NULL
promoters	NULL
by	NULL
the	NULL
dominant	NULL
negative	NULL
mutant	NULL
NFATcA418	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
sample	NULL
7	NULL
and	NULL
Figure	NULL
5	NULL
,	NULL
sample	NULL
7	NULL
)	NULL
suggests	NULL
that	NULL
Tpl-2	NULL
acts	NULL
through	NULL
both	NULL
CsA-sensitive	NULL
and	NULL
CsA	NULL
-insensitive	NULL
pathways	NULL
to	NULL
activate	NULL
NFAT	NULL
.	NULL

A	NULL
CsA	NULL
insensitive	NULL
pathway	NULL
which	NULL
is	NULL
activated	NULL
by	NULL
PMA	NULL
and	NULL
CD28	NULL
co-stimulation	NULL
has	NULL
been	NULL
previously	NULL
reported	NULL
(	NULL
Ghosh	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

This	NULL
pathway	NULL
activates	NULL
NFATp	NULL
NFAT/CAT	NULL
50	NULL
Relative	NULL
CAT	NULL
activity	NULL
L	NULL
o	NULL
ZZ	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
10	NULL
2	NULL
Raf-1	NULL
Y340D	NULL
~	NULL
+	NULL
Figure	NULL
3	NULL
Activation	NULL
of	NULL
NFAT	NULL
is	NULL
induced	NULL
by	NULL
a	NULL
combination	NULL
of	NULL
activated	NULL
Rafl	NULL
and	NULL
NFATc	NULL
or	NULL
activated	NULL
CnA	NULL
.	NULL

EL4	NULL
cells	NULL
were	NULL
transiently	NULL
cotransfected	NULL
with	NULL
the	NULL
pSPNFATCAT	NULL
(	NULL
NFAT/CAT	NULL
)	NULL
reporter	NULL
construct	NULL
and	NULL
Raf1Y340D	NULL
or	NULL
Raf1Y340D	NULL
and	NULL
NFATc	NULL
,	NULL
NFATp	NULL
,	NULL
NFATx	NULL
,	NULL
CAML	NULL
,	NULL
ACnA	NULL
,	NULL
or	NULL
v-Ha-ras	NULL
in	NULL
the	NULL
indicated	NULL
combinations	NULL
.	NULL

Control	NULL
cultures	NULL
of	NULL
the	NULL
same	NULL
cells	NULL
were	NULL
transfected	NULL
only	NULL
with	NULL
the	NULL
reporter	NULL
or	NULL
with	NULL
the	NULL
reporter	NULL
in	NULL
combination	NULL
with	NULL
Tpl-2	NULL
.	NULL

Transfections	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
quadruplicate	NULL
.	NULL

Forty-eight	NULL
hours	NULL
later	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
CAT	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
the	NULL
lysates	NULL
.	NULL

Activity	NULL
was	NULL
quantitated	NULL
by	NULL
phospho-imager	NULL
2611	NULL
Tpl-2	NULL
activates	NULL
NFAT	NULL
and	NULL
NF-xB	NULL
C	NULL
Tsatsanis	NULL
et	NULL
al	NULL
2612	NULL
which	NULL
is	NULL
also	NULL
selectively	NULL
activated	NULL
by	NULL
Tpl-2	NULL
(	NULL
Tsatsanis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

Evidence	NULL
presented	NULL
in	NULL
Figure	NULL
4b	NULL
shows	NULL
that	NULL
v-Ha-Ras	NULL
,	NULL
similar	NULL
to	NULL
Tpl-2	NULL
,	NULL
is	NULL
sufficient	NULL
to	NULL
activate	NULL
NFAT	NULL
in	NULL
EL-4	NULL
cells	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
dominant	NULL
negative	NULL
mutant	NULL
Ha-RasN17	NULL
blocks	NULL
the	NULL
Tpl-2-mediated	NULL
activation	NULL
of	NULL
NFAT	NULL
(	NULL
Figure	NULL
5	NULL
,	NULL
sample	NULL
3	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
while	NULL
the	NULL
activation	NULL
of	NULL
NFAT	NULL
by	NULL
Tpl-2	NULL
is	NULL
only	NULL
partially	NULL
blocked	NULL
by	NULL
CsA	NULL
(	NULL
Figure	NULL
4b	NULL
,	NULL
sample	NULL
7	NULL
)	NULL
the	NULL
activation	NULL
of	NULL
NFAT	NULL
A	NULL
.	NULL

B.	NULL
IL-2/CAT	NULL
Fad	NULL
B	NULL
>	NULL
2	NULL
``	NULL
ts	NULL
i*	NULL
)	NULL
g	NULL
S	NULL
|—	NULL
&	NULL
<	NULL
4	NULL
0	NULL
<	NULL
o	NULL
o	NULL
o	NULL
B	NULL
=	NULL
I	NULL
50	NULL
S	NULL
;	NULL
&	NULL
&	NULL
o	NULL
0	NULL
o~	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
Tpl-2	NULL
wt	NULL
-	NULL
+00	NULL
#	NULL
0	NULL
=	NULL
o=	NULL
v-Ha-Ras	NULL
PMA/iono	NULL
-	NULL
-o	NULL
-	NULL
+0	NULL
+	NULL
Raf	NULL
Y340D	NULL
CsA	NULL
-	NULL
-	NULL
+0	NULL
~	NULL
+	NULL
Tpl-2	NULL
wt	NULL
Tpl-2	NULL
tr	NULL
.	NULL

PMA/iono	NULL
.	NULL

CsA	NULL
C.	NULL
NFAT/CAT	NULL
&	NULL
100	NULL
2	NULL
shat	NULL
o	NULL
®	NULL
-I	NULL
t-	NULL
<	NULL
UO	NULL
0	NULL
50	NULL
2	NULL
gas	NULL
S	NULL
o	NULL
CC	NULL
0—	NULL
Tpl-2	NULL
wt	NULL
Bel-2	NULL
Mel-1	NULL
_	NULL
-	NULL
=	NULL
=	NULL
=	NULL
==	NULL
o	NULL
#	NULL
Bel-xL	NULL
-	NULL
=-	NULL
=	NULL
=	NULL
-o	NULL
+	NULL
PMA/iona	NULL
.	NULL

-	NULL
=-	NULL
+	NULL
==	NULL
=	NULL
by	NULL
v-Ha-Ras	NULL
is	NULL
fully	NULL
blocked	NULL
by	NULL
this	NULL
inhibitor	NULL
(	NULL
Figure	NULL
4b	NULL
,	NULL
sample	NULL
3	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
calcineurin/NFAT	NULL
pathway	NULL
by	NULL
Tpl-2	NULL
depends	NULL
on	NULL
a	NULL
combination	NULL
of	NULL
Ras-dependent	NULL
and	NULL
independent	NULL
signals	NULL
.	NULL

The	NULL
Ras-independent	NULL
signal	NULL
is	NULL
not	NULL
inhibited	NULL
by	NULL
CsA	NULL
and	NULL
therefore	NULL
operates	NULL
downstream	NULL
of	NULL
calcineurin	NULL
.	NULL

Co-expression	NULL
of	NULL
Tpl-2	NULL
with	NULL
Bcel-2	NULL
or	NULL
Bel-X	NULL
;	NULL
,	NULL
,	NULL
but	NULL
not	NULL
Mcl-1	NULL
fully	NULL
inhibited	NULL
the	NULL
Tpl-2-induced	NULL
NFAT	NULL
activa-	NULL
NFAT/CAT	NULL
+	NULL
U	NULL
U	NULL
U	NULL
+	NULL
U	NULL
+	NULL
Figure	NULL
4	NULL
(	NULL
a	NULL
)	NULL
Tpl-2	NULL
-	NULL
induced	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
is	NULL
only	NULL
partially	NULL
inhibited	NULL
by	NULL
CsA	NULL
.	NULL

EL4	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
a	NULL
Tpl-2	NULL
expression	NULL
construct	NULL
and	NULL
an	NULL
IL-2/CAT	NULL
reporter	NULL
plasmid	NULL
and	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
were	NULL
treated	NULL
with	NULL
CsA	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Tpl-2	NULL
and	NULL
v-Ha-ras	NULL
activate	NULL
the	NULL
NFAT/SV40	NULL
promoter	NULL
but	NULL
v-Ha-ras-mediated	NULL
activation	NULL
is	NULL
inhibited	NULL
fully	NULL
,	NULL
while	NULL
Tpl-2-mediated	NULL
activation	NULL
is	NULL
inhibited	NULL
only	NULL
partially	NULL
by	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
.	NULL

EL4	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
v-Ha-ras	NULL
or	NULL
Tpl-2	NULL
(	NULL
wild-type	NULL
or	NULL
truncated	NULL
)	NULL
and	NULL
the	NULL
NFAT/CAT	NULL
reporter	NULL
construct	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
CsA	NULL
as	NULL
indicated	NULL
.	NULL

Control	NULL
cultures	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
with	NULL
or	NULL
without	NULL
CsA	NULL
,	NULL
also	NULL
as	NULL
indicated	NULL
.	NULL

CsA	NULL
was	NULL
added	NULL
at	NULL
24	NULL
h	NULL
following	NULL
transfection	NULL
and	NULL
PMA	NULL
and	NULL
ionomycin	NULL
at	NULL
36	NULL
h	NULL
following	NULL
transfection	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
at	NULL
48	NULL
h	NULL
following	NULL
transfection	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
the	NULL
cell	NULL
lysates	NULL
and	NULL
was	NULL
quantitated	NULL
by	NULL
phospho-imager	NULL
.	NULL

Transfections	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
quadruplicate	NULL
.	NULL

Expression	NULL
was	NULL
normalized	NULL
based	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
$	NULL
-Gal	NULL
from	NULL
a	NULL
cotransfected	NULL
CMV	NULL
5/	NULL
$	NULL
-Gal	NULL
construct	NULL
.	NULL

(	NULL
¢	NULL
)	NULL
Activation	NULL
of	NULL
NFAT	NULL
by	NULL
Tpl-2	NULL
is	NULL
inhibited	NULL
by	NULL
Bel-2	NULL
and	NULL
Bel-X	NULL
;	NULL
,	NULL
but	NULL
not	NULL
by	NULL
Mcl-1	NULL
.	NULL

EL4	NULL
cells	NULL
were	NULL
co-transfected	NULL
with	NULL
Tpl-2	NULL
and	NULL
the	NULL
corresponding	NULL
expression	NULL
constructs	NULL
and	NULL
the	NULL
NFAT/CAT	NULL
reporter	NULL
plasmid	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
measured	NULL
as	NULL
described	NULL
.	NULL

Each	NULL
bar	NULL
represents	NULL
the	NULL
average	NULL
of	NULL
triplicate	NULL
samples	NULL
.	NULL

The	NULL
experiment	NULL
was	NULL
repeated	NULL
at	NULL
least	NULL
three	NULL
times	NULL
tion	NULL
(	NULL
Figure	NULL
4¢c	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
that	NULL
Bcl-2	NULL
and	NULL
Bcl-X	NULL
;	NULL
inhibit	NULL
both	NULL
signals	NULL
.	NULL

Similarly	NULL
,	NULL
activation	NULL
of	NULL
NFAT	NULL
by	NULL
PMA	NULL
and	NULL
ionomycin	NULL
was	NULL
fully	NULL
blocked	NULL
by	NULL
Bcl-2	NULL
and	NULL
Bcl-X	NULL
,	NULL
but	NULL
not	NULL
Mcl-1	NULL
(	NULL
Figure	NULL
4c¢c	NULL
)	NULL
.	NULL

Earlier	NULL
studies	NULL
had	NULL
shown	NULL
that	NULL
Bcl-2	NULL
binds	NULL
calcineurin	NULL
A	NULL
at	NULL
the	NULL
catalytic	NULL
domain	NULL
and	NULL
sequesters	NULL
it	NULL
at	NULL
the	NULL
plasma	NULL
membrane	NULL
,	NULL
thus	NULL
preventing	NULL
it	NULL
from	NULL
dephosphorylating	NULL
NFAT	NULL
(	NULL
Shibasaki	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
by	NULL
which	NULL
Bcl-2	NULL
and	NULL
Bcl-X	NULL
;	NULL
block	NULL
the	NULL
signal	NULL
operating	NULL
downstream	NULL
of	NULL
calcineurin	NULL
remains	NULL
unknown	NULL
.	NULL

The	NULL
dominant	NULL
negative	NULL
mutant	NULL
MEK1S218/222A	NULL
blocks	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
but	NULL
not	NULL
the	NULL
NFAT-driven	NULL
promoter	NULL
by	NULL
Tpl-2	NULL
The	NULL
experiment	NULL
on	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter/CAT	NULL
reporter	NULL
shown	NULL
in	NULL
Figure	NULL
1	NULL
was	NULL
repeated	NULL
with	NULL
the	NULL
NFAT/CAT	NULL
reporter	NULL
construct	NULL
.	NULL

The	NULL
pattern	NULL
of	NULL
inhibition	NULL
of	NULL
the	NULL
NFAT-driven	NULL
promoter	NULL
by	NULL
the	NULL
dominant	NULL
negative	NULL
mutants	NULL
shown	NULL
in	NULL
Figure	NULL
5	NULL
was	NULL
identical	NULL
to	NULL
the	NULL
pattern	NULL
of	NULL
inhibition	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
the	NULL
same	NULL
mutants	NULL
with	NULL
the	NULL
exception	NULL
of	NULL
MEK1§8218/222A	NULL
which	NULL
inhibited	NULL
fully	NULL
the	NULL
Tpl-2-induced	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
but	NULL
only	NULL
partially	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
NFAT-driven	NULL
promoter	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
using	NULL
the	NULL
MEK	NULL
inhibitor	NULL
PDO098059	NULL
(	NULL
Parke-Davis	NULL
Pharmaceuticals	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
activation	NULL
of	NULL
NFAT	NULL
is	NULL
MAPK-dependent	NULL
these	NULL
findings	NULL
suggest	NULL
that	NULL
the	NULL
Tpl-2-mediated	NULL
activation	NULL
of	NULL
MAPK	NULL
is	NULL
,	NULL
at	NULL
least	NULL
partially	NULL
,	NULL
independent	NULL
of	NULL
MEK	NULL
1	NULL
or	NULL
MEK	NULL
.	NULL

Tpl-2	NULL
activates	NULL
the	NULL
MAPK	NULL
ERK1	NULL
via	NULL
a	NULL
MEKI	NULL
!	NULL

-independent	NULL
pathway	NULL
To	NULL
test	NULL
the	NULL
hypothesis	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
MAPK	NULL
by	NULL
Tpl-2	NULL
is	NULL
MEK	NULL
l-independent	NULL
we	NULL
examined	NULL
whether	NULL
MEK1	NULL
is	NULL
required	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
MAPK	NULL
ERK	NULL
1	NULL
by	NULL
Tpl-2	NULL
in	NULL
COS-1	NULL
cells	NULL
.	NULL

Overexpression	NULL
of	NULL
the	NULL
dominant	NULL
negative	NULL
mutant	NULL
MEK	NULL
18218/222A	NULL
inhibited	NULL
minimally	NULL
the	NULL
activation	NULL
of	NULL
ERK1	NULL
by	NULL
Tpl-2	NULL
while	NULL
it	NULL
inhibited	NULL
fully	NULL
the	NULL
activation	NULL
of	NULL
ERK	NULL
1	NULL
by	NULL
EGF	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
the	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
the	NULL
MEK	NULL
inhibitor	NULL
PDO098059	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
.	NULL

This	NULL
observation	NULL
confirmed	NULL
that	NULL
Tpl-2	NULL
activates	NULL
the	NULL
MAPK	NULL
and	NULL
showed	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
MAPK	NULL
by	NULL
Tpl-2	NULL
is	NULL
at	NULL
least	NULL
in	NULL
part	NULL
MEK	NULL
1/MEK2-independent	NULL
.	NULL

Tpl-2	NULL
activates	NULL
NF-kB	NULL
by	NULL
a	NULL
MEK-dependent	NULL
mechanism	NULL
.	NULL

NF-kB	NULL
activation	NULL
is	NULL
required	NULL
for	NULL
Tpl-2-mediated	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
The	NULL
difference	NULL
between	NULL
the	NULL
IL-2	NULL
and	NULL
NFAT	NULL
promoters	NULL
regarding	NULL
their	NULL
induction	NULL
by	NULL
Tpl-2	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
MEK	NULL
18218/222A	NULL
suggests	NULL
that	NULL
Tpl-2	NULL
may	NULL
regulate	NULL
the	NULL
activity	NULL
of	NULL
additional	NULL
transcription	NULL
factors	NULL
that	NULL
contribute	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
and	NULL
are	NULL
activated	NULL
via	NULL
a	NULL
MEK1/MEK2-dependent	NULL
mechanism	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
relies	NULL
on	NULL
the	NULL
simultaneous	NULL
activation	NULL
of	NULL
the	NULL
transcription	NULL
factors	NULL
NFAT	NULL
,	NULL
API	NULL
,	NULL
NF-xB	NULL
and	NULL
Oct	NULL
(	NULL
Figure	NULL
7a	NULL
)	NULL
(	NULL
Garrity	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Rooney	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Of	NULL
these	NULL
,	NULL
NFAT	NULL
and	NULL
NF-xB	NULL
are	NULL
obligatory	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Thus	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
NF-xB	NULL
binding	NULL
site	NULL
or	NULL
one	NULL
of	NULL
the	NULL
NFAT	NULL
sites	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
blocked	NULL
Tpl-2	NULL
activates	NULL
NFAT	NULL
and	NULL
NF-xB	NULL
C	NULL
Tsatsanis	NULL
et	NULL
al	NULL
its	NULL
responsiveness	NULL
to	NULL
either	NULL
Tpl-2	NULL
or	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
Figure	NULL
7b	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
overexpression	NULL
of	NULL
Ik-Ba	NULL
inhibited	NULL
the	NULL
Tpl-2	NULL
mediated	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
Figure	NULL
7¢	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
tested	NULL
whether	NULL
Tpl-2	NULL
activates	NULL
NF-xB	NULL
,	NULL
and	NULL
whether	NULL
the	NULL
potential	NULL
activation	NULL
of	NULL
this	NULL
factor	NULL
is	NULL
MEK	NULL
-dependent	NULL
.	NULL

The	NULL
data	NULL
in	NULL
Figure	NULL
7d	NULL
revealed	NULL
that	NULL
Tpl-2	NULL
indeed	NULL
activates	NULL
NF-xB	NULL
in	NULL
EL4	NULL
cells	NULL
and	NULL
that	NULL
the	NULL
dominant	NULL
negative	NULL
mutants	NULL
MEK	NULL
18218/222A	NULL
,	NULL
Ha-Ras	NULL
NFAT/CAT	NULL
100	NULL
7	NULL
50	NULL
Relative	NULL
CAT	NULL
activity	NULL
Tpl-2	NULL
wt	NULL
PMA/iono	NULL
c-Ha-Ras	NULL
N17	NULL
Raf-1	NULL
S621A	NULL
MEK1	NULL
$	NULL
218/222A	NULL
SEK1	NULL
K299R	NULL
NFATe	NULL
A	NULL
418	NULL
wn	NULL
a	NULL
a	NULL
a	NULL
b	NULL
,	NULL
a	NULL
2	NULL
+	NULL
6064	NULL
d	NULL
g.	NULL
d	NULL
gets	NULL
5	NULL
6	NULL
+	NULL
+	NULL
+	NULL
=	NULL
-	NULL
+	NULL
+lllll+q2	NULL
Koa	NULL
aa	NULL
d	NULL
get	NULL
ge	NULL
Figure	NULL
5	NULL
Activation	NULL
of	NULL
the	NULL
NFAT/CAT	NULL
reporter	NULL
by	NULL
Tpl-2	NULL
was	NULL
inhibited	NULL
by	NULL
different	NULL
dominant	NULL
inhibitory	NULL
mutants	NULL
of	NULL
the	NULL
MAPK	NULL
and	NULL
the	NULL
Calcineurin/NFAT	NULL
pathways	NULL
.	NULL

EL4	NULL
cells	NULL
were	NULL
transiently	NULL
cotransfected	NULL
with	NULL
Tpl-2	NULL
expressing	NULL
construct	NULL
,	NULL
the	NULL
corresponding	NULL
expression	NULL
plasmid	NULL
of	NULL
the	NULL
dominant	NULL
negative	NULL
mutant	NULL
and	NULL
an	NULL
NFAT/CAT	NULL
reporter	NULL
plasmid	NULL
.	NULL

Transfections	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
quadruplicate	NULL
.	NULL

Forty-eight	NULL
hours	NULL
later	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
CAT	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
the	NULL
lysates	NULL
.	NULL

Activity	NULL
was	NULL
quantitated	NULL
by	NULL
phospho-imager	NULL
1	NULL
2	NULL
3	NULL
-	NULL
4	NULL
5°	NULL
60	NULL
7	NULL
Cre	NULL
PD98059	NULL
*	NULL
*	NULL
+	NULL
*	NULL
*	NULL
+	NULL
MEK1	NULL
$	NULL
218/222A	NULL
~	NULL
+	NULL
~	NULL
~	NULL
*	NULL
*	NULL
Tpl-2wt	NULL
_	NULL
>	NULL
h	NULL
=	NULL
=	NULL
400	NULL
4+	NULL
00+	NULL
HA.ERK1	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
I	NULL
HA.pd44ERKUMBP	NULL
-	NULL
>	NULL
Cap	NULL
--	NULL
ﬂ	NULL
Kinase	NULL
assay	NULL
HA.p44ERK1	NULL
>	NULL
cums	NULL
comes	NULL
eee	NULL
Chm	NULL
am	NULL
cmm	NULL
Western	NULL
blot	NULL
HI	NULL
>	NULL
amme	NULL
Western	NULL
blot	NULL
MEK1	NULL
8218/2224	NULL
>	NULL
am	NULL
C	NULL
Western	NULL
blot	NULL
Figure	NULL
6	NULL
Activation	NULL
of	NULL
the	NULL
MAPK	NULL
by	NULL
Tpl-2	NULL
is	NULL
ERKI	NULL
independent	NULL
.	NULL

COS-1	NULL
cells	NULL
were	NULL
co-transfected	NULL
with	NULL
HA-tagged	NULL
ERKI1	NULL
and	NULL
wild-type	NULL
Tpl-2	NULL
as	NULL
indicated	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
with	NULL
EGF1	NULL
where	NULL
indicated	NULL
.	NULL

ERK	NULL
1	NULL
kinase	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
the	NULL
immunoprecipitate	NULL
(	NULL
panel	NULL
I	NULL
)	NULL
.	NULL

The	NULL
p44ERK	NULL
1	NULL
(	NULL
panel	NULL
II	NULL
)	NULL
,	NULL
Tpl2	NULL
(	NULL
panel	NULL
III	NULL
)	NULL
and	NULL
MEK	NULL
1§218/222A	NULL
(	NULL
panel	NULL
IV	NULL
)	NULL
protein	NULL
expression	NULL
was	NULL
measured	NULL
in	NULL
the	NULL
total	NULL
lysate	NULL
2613	NULL
Tpl-2	NULL
activates	NULL
NFAT	NULL
and	NULL
NF-xB	NULL
C	NULL
Tsatsanis	NULL
et	NULL
al	NULL
2614	NULL
A.	NULL
NFAT	NULL
*	NULL
API	NULL
Oct	NULL
NFkB	NULL
*	NULL
NFAT	NULL
*	NULL
API	NULL
NFAT	NULL
API	NULL
NFAT	NULL
API	NULL
Oct	NULL
NFATAP1	NULL
+1	NULL
(	NULL
-280	NULL
)	NULL
(	NULL
-205	NULL
)	NULL
-	NULL
(	NULL
-160	NULL
)	NULL
(	NULL
135	NULL
)	NULL
(	NULL
-90	NULL
)	NULL
(	NULL
45	NULL
)	NULL
B.	NULL
g	NULL
-I	NULL
2	NULL
I	NULL
1007	NULL
©	NULL
t-	NULL
<	NULL
=	NULL
O	NULL
0	NULL
.2	NULL
50	NULL
shut	NULL
3	NULL
©	NULL
CC	NULL
_-0	NULL
T	NULL
1	NULL
wt	NULL
IL-2CAT	NULL
+	NULL
+	NULL
=	NULL
=	NULL
=	NULL
+	NULL
=	NULL
=	NULL
=	NULL
(	NULL
-205	NULL
)	NULL
NF	NULL
<	NULL
B*	NULL
=	NULL
-	NULL
+	NULL
=	NULL
=	NULL
=	NULL
+	NULL
=	NULL
=	NULL
(	NULL
-280	NULL
)	NULL
NFAT*	NULL
=	NULL
=	NULL
=	NULL
+	NULL
=	NULL
=	NULL
=	NULL
+	NULL
=	NULL
(	NULL
-160	NULL
)	NULL
NFAT*	NULL
=	NULL
=	NULL
=	NULL
=	NULL
+	NULL
=	NULL
=	NULL
=	NULL
+	NULL
Tpl-2	NULL
wt	NULL
=	NULL
+	NULL
+	NULL
+	NULL
+	NULL
=	NULL
=	NULL
a	NULL
PMA	NULL
/	NULL
iono	NULL
.	NULL

=-	NULL
-	NULL
-	NULL
=	NULL
=	NULL
+	NULL
+	NULL
+	NULL
#	NULL
C.	NULL
D.	NULL
IL-2	NULL
/	NULL
CAT	NULL
NFkB/CAT	NULL
100	NULL
-	NULL
_	NULL
]	NULL
-|-	NULL
Relative	NULL
CAT	NULL
activity	NULL
Relative	NULL
CAT	NULL
activity	NULL
1	NULL
2	NULL
3	NULL
4	NULL
Tpl-2	NULL
wt	NULL
=-	NULL
+	NULL
+	NULL
=	NULL
Tpl-2	NULL
wt	NULL
=	NULL
+	NULL
+	NULL
+	NULL
+	NULL
=	NULL
IkB-a	NULL
_-	NULL
-	NULL
-=	NULL
+	NULL
=	NULL
PMA	NULL
/	NULL
iono	NULL
.	NULL

=	NULL
=	NULL
=	NULL
=	NULL
=-	NULL
+	NULL
PMA	NULL
/iono	NULL
-	NULL
=-	NULL
o=	NULL
+	NULL
MEK1	NULL
$	NULL
218/222A	NULL
=	NULL
=	NULL
e	NULL
s	NULL
=	NULL
=	NULL
=	NULL
Ha-Ras	NULL
N17	NULL
=	NULL
=	NULL
=	NULL
+	NULL
=	NULL
=	NULL
Rafi	NULL
S621A	NULL
=	NULL
=	NULL
=	NULL
-	NULL
+	NULL
=	NULL
Figure	NULL
7	NULL
(	NULL
a	NULL
)	NULL
Diagrammatic	NULL
representation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

The	NULL
binding	NULL
sites	NULL
noted	NULL
with	NULL
an	NULL
asterisk	NULL
were	NULL
mutated	NULL
in	NULL
the	NULL
corresponding	NULL
constructs	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Mutation	NULL
of	NULL
the	NULL
NF-xB	NULL
or	NULL
NFAT	NULL
binding	NULL
sites	NULL
on	NULL
the	NULL
IL-2	NULL
promoter	NULL
abolishes	NULL
its	NULL
ability	NULL
to	NULL
be	NULL
activated	NULL
either	NULL
by	NULL
Tpl-2	NULL
or	NULL
by	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

EL4	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
wild-type	NULL
or	NULL
truncated	NULL
Tpl-2	NULL
and	NULL
the	NULL
corresponding	NULL
mutant	NULL
promoters	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
48	NULL
h	NULL
after	NULL
transfection	NULL
and	NULL
CAT	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
the	NULL
cell	NULL
lysates	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
methods	NULL
.	NULL

Where	NULL
indicated	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
8	NULL
h	NULL
prior	NULL
to	NULL
harvesting	NULL
.	NULL

(	NULL
¢	NULL
)	NULL
Ix-Ba	NULL
overexpression	NULL
inhibits	NULL
the	NULL
Tpl-2	NULL
mediated	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

EL4	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
Tpl-2	NULL
and	NULL
the	NULL
wild-type	NULL
Ix-B	NULL
«	NULL
expression	NULL
constructs	NULL
and	NULL
an	NULL
IL-2/CAT	NULL
reporter	NULL
construct	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
measured	NULL
as	NULL
described	NULL
.	NULL

Transfection	NULL
efficiency	NULL
was	NULL
monitored	NULL
by	NULL
expression	NULL
of	NULL
B-Gal	NULL
.	NULL

(	NULL
d	NULL
)	NULL
NF-xB	NULL
activation	NULL
by	NULL
Tpl-2	NULL
is	NULL
MEK	NULL
1	NULL
,	NULL
Ha-Ras	NULL
and	NULL
Rafl	NULL
dependent	NULL
.	NULL

EL4	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
Tpl-2	NULL
and	NULL
the	NULL
dominant	NULL
negative	NULL
mutants	NULL
MEK	NULL
18218/222A	NULL
,	NULL
Ha-Ras	NULL
N17	NULL
,	NULL
Rafl	NULL
S621	NULL
and	NULL
a	NULL
CAT	NULL
reporter	NULL
construct	NULL
containing	NULL
6	NULL
NF-xB	NULL
binding	NULL
sites	NULL
upstream	NULL
the	NULL
TK	NULL
minimal	NULL
promoter	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
measured	NULL
as	NULL
described	NULL
Extracellular	NULL
signals	NULL
[	NULL
binding	NULL
site	NULL
ra	NULL
y	NULL
``	NULL
y	NULL
NFAT	NULL
nucleus	NULL
NFAT	NULL
binding	NULL
site	NULL
]	NULL
Figure	NULL
8	NULL
-	NULL
Model	NULL
of	NULL
Tpl-2	NULL
mediated	NULL
activation	NULL
of	NULL
NFAT	NULL
and	NULL
NF-xB	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
NFAT	NULL
and	NULL
NF-xB	NULL
can	NULL
be	NULL
induced	NULL
either	NULL
by	NULL
TCR	NULL
stimulation	NULL
or	NULL
pharmacologically	NULL
using	NULL
ionomycin	NULL
,	NULL
which	NULL
stimulates	NULL
calcium	NULL
influx	NULL
,	NULL
and	NULL
PMA	NULL
which	NULL
activates	NULL
PKC	NULL
.	NULL

Tpl-2	NULL
transduces	NULL
some	NULL
of	NULL
these	NULL
signals	NULL
leading	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
NFAT	NULL
and	NULL
NF-xB	NULL
N17	NULL
and	NULL
Rafl8621A	NULL
block	NULL
its	NULL
activation	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
Tpl-2	NULL
activates	NULL
NF-xB	NULL
in	NULL
a	NULL
MEK	NULL
1-dependent	NULL
and	NULL
NFAT	NULL
in	NULL
a	NULL
MEK	NULL
1-independent	NULL
fashion	NULL
.	NULL

Discussion	NULL
In	NULL
the	NULL
present	NULL
study	NULL
we	NULL
examined	NULL
the	NULL
pathways	NULL
through	NULL
which	NULL
Tpl-2	NULL
activates	NULL
NFAT	NULL
and	NULL
induces	NULL
expression	NULL
of	NULL
IL-2	NULL
in	NULL
lymphoid	NULL
cell	NULL
lines	NULL
.	NULL

The	NULL
results	NULL
show	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
both	NULL
the	NULL
IL-2	NULL
promoter	NULL
and	NULL
an	NULL
NFAT	NULL
regulated	NULL
basal	NULL
SV40	NULL
promoter	NULL
by	NULL
Tpl-2	NULL
is	NULL
mediated	NULL
by	NULL
the	NULL
MAPK	NULL
pathway	NULL
in	NULL
combination	NULL
with	NULL
the	NULL
calcium	NULL
dependent	NULL
calcineurin/NFAT	NULL
pathway	NULL
.	NULL

Inhibition	NULL
of	NULL
the	NULL
MAPK	NULL
or	NULL
the	NULL
calcineurin	NULL
pathway	NULL
abrogated	NULL
IL-2	NULL
and	NULL
NFAT	NULL
promoter	NULL
activation	NULL
by	NULL
Tpl-2	NULL
.	NULL

These	NULL
findings	NULL
led	NULL
us	NULL
to	NULL
propose	NULL
the	NULL
model	NULL
of	NULL
NFAT	NULL
and	NULL
IL-2	NULL
promoter	NULL
activation	NULL
by	NULL
Tpl-2	NULL
shown	NULL
in	NULL
Figure	NULL
8	NULL
.	NULL

This	NULL
model	NULL
takes	NULL
into	NULL
account	NULL
the	NULL
fact	NULL
that	NULL
NFAT	NULL
is	NULL
a	NULL
complex	NULL
factor	NULL
composed	NULL
of	NULL
API	NULL
and	NULL
NFAT	NULL
components	NULL
(	NULL
Northrop	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
MAPK	NULL
by	NULL
Tpl-2	NULL
according	NULL
to	NULL
this	NULL
model	NULL
occurs	NULL
through	NULL
at	NULL
least	NULL
two	NULL
distinct	NULL
signals	NULL
,	NULL
one	NULL
that	NULL
is	NULL
MEK-dependent	NULL
and	NULL
one	NULL
that	NULL
is	NULL
MEK	NULL
-independent	NULL
.	NULL

Both	NULL
the	NULL
MEK-dependent	NULL
and	NULL
independent	NULL
signals	NULL
are	NULL
transduced	NULL
via	NULL
Ha-ras	NULL
and	NULL
Rafl	NULL
.	NULL

Therefore	NULL
,	NULL
Tpl-2	NULL
signals	NULL
activating	NULL
the	NULL
MAPK	NULL
diverge	NULL
downstream	NULL
of	NULL
Rafl	NULL
.	NULL

Tpl-2	NULL
also	NULL
initiates	NULL
signals	NULL
that	NULL
activate	NULL
NFAT	NULL
(	NULL
Tsatsanis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

These	NULL
signals	NULL
are	NULL
inhibited	NULL
by	NULL
cyclosporin	NULL
only	NULL
partially	NULL
,	NULL
suggesting	NULL
that	NULL
Tpl-2	NULL
operates	NULL
both	NULL
upstream	NULL
and	NULL
downstream	NULL
of	NULL
calcineurin	NULL
.	NULL

The	NULL
same	NULL
signals	NULL
are	NULL
fully	NULL
blocked	NULL
by	NULL
Bel-2	NULL
and	NULL
Bel-X	NULL
;	NULL
.	NULL

Combination	NULL
of	NULL
the	NULL
above	NULL
signals	NULL
leads	NULL
to	NULL
the	NULL
activation	NULL
and	NULL
nuclear	NULL
translocation	NULL
of	NULL
NFAT	NULL
and	NULL
NF-xB	NULL
,	NULL
two	NULL
transcription	NULL
factors	NULL
,	NULL
that	NULL
are	NULL
obligatory	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

According	NULL
to	NULL
this	NULL
model	NULL
,	NULL
NFAT	NULL
is	NULL
activated	NULL
via	NULL
the	NULL
convergence	NULL
of	NULL
the	NULL
MAPK	NULL
pathway	NULL
that	NULL
contributes	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
API	NULL
component	NULL
of	NULL
NFAT	NULL
,	NULL
and	NULL
the	NULL
calcineurin	NULL
NFAT	NULL
pathway	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
inhibition	NULL
of	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
and	NULL
the	NULL
NFAT	NULL
promoter	NULL
by	NULL
the	NULL
dominant	NULL
negative	NULL
mutant	NULL
SEKIK299R	NULL
suggests	NULL
Tpl-2	NULL
activates	NULL
NFAT	NULL
and	NULL
NF-xB	NULL
C	NULL
Tsatsanis	NULL
et	NULL
al	NULL
that	NULL
the	NULL
contribution	NULL
of	NULL
the	NULL
SAPK	NULL
pathway	NULL
may	NULL
not	NULL
be	NULL
critical	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
NFAT	NULL
by	NULL
Tpl-2	NULL
.	NULL

Alternatively	NULL
,	NULL
SAPK	NULL
may	NULL
be	NULL
activated	NULL
by	NULL
pathways	NULL
(	NULL
Su	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
that	NULL
are	NULL
SEK	NULL
1	NULL
-independent	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
NFAT-regulated	NULL
minimal	NULL
promoter	NULL
in	NULL
EL4	NULL
cells	NULL
following	NULL
transient	NULL
transfection	NULL
of	NULL
activated	NULL
Rafl	NULL
(	NULL
Raf1	NULL
Y340D	NULL
)	NULL
and	NULL
activated	NULL
calcineurin	NULL
(	NULL
ACnA¥	NULL
)	NULL
or	NULL
activated	NULL
NFATc	NULL
provided	NULL
support	NULL
to	NULL
this	NULL
model	NULL
.	NULL

Additional	NULL
support	NULL
was	NULL
provided	NULL
by	NULL
experiments	NULL
comparing	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
and	NULL
the	NULL
NFAT-regulated	NULL
minimal	NULL
SV40	NULL
promoter	NULL
in	NULL
EL4	NULL
and	NULL
Jurkat	NULL
cells	NULL
.	NULL

Data	NULL
presented	NULL
here	NULL
show	NULL
that	NULL
the	NULL
carboxy-terminally	NULL
truncated	NULL
Tpl-2	NULL
activates	NULL
NFAT	NULL
in	NULL
both	NULL
cell	NULL
lines	NULL
,	NULL
while	NULL
the	NULL
wild-type	NULL
Tpl-2	NULL
activates	NULL
NFAT	NULL
only	NULL
in	NULL
EL4	NULL
cells	NULL
Since	NULL
the	NULL
EL4	NULL
cells	NULL
express	NULL
a	NULL
mutant	NULL
calcineurin	NULL
(	NULL
CnA	NULL
D477N	NULL
)	NULL
which	NULL
exhibits	NULL
enhanced	NULL
sensitivity	NULL
to	NULL
increases	NULL
in	NULL
the	NULL
cytoplasmic	NULL
calcium	NULL
levels	NULL
,	NULL
and	NULL
is	NULL
therefore	NULL
partially	NULL
activated	NULL
(	NULL
Fruman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
we	NULL
hypothesized	NULL
that	NULL
the	NULL
enhanced	NULL
responsiveness	NULL
of	NULL
EL4	NULL
cells	NULL
to	NULL
Tpl-2	NULL
is	NULL
due	NULL
to	NULL
the	NULL
lower	NULL
threshold	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
calcineurin	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

To	NULL
address	NULL
this	NULL
hypothesis	NULL
,	NULL
we	NULL
cotransfected	NULL
Jurkat	NULL
cells	NULL
with	NULL
wild-type	NULL
Tpl-2	NULL
in	NULL
combination	NULL
with	NULL
an	NULL
expression	NULL
construct	NULL
of	NULL
an	NULL
activated	NULL
mutant	NULL
of	NULL
calcineurin	NULL
(	NULL
ACnA¥	NULL
)	NULL
.	NULL

The	NULL
results	NULL
provided	NULL
support	NULL
for	NULL
the	NULL
model	NULL
by	NULL
showing	NULL
that	NULL
the	NULL
combination	NULL
of	NULL
the	NULL
two	NULL
activates	NULL
NFAT	NULL
and	NULL
induces	NULL
IL-2	NULL
expression	NULL
.	NULL

According	NULL
to	NULL
the	NULL
model	NULL
in	NULL
Figure	NULL
8	NULL
,	NULL
Ras	NULL
plays	NULL
a	NULL
central	NULL
role	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
NFAT	NULL
by	NULL
Tpl-2	NULL
.	NULL

Data	NULL
presented	NULL
here	NULL
indeed	NULL
show	NULL
that	NULL
Ha-ras-N17	NULL
,	NULL
a	NULL
dominant	NULL
negative	NULL
mutant	NULL
of	NULL
Ha-ras	NULL
,	NULL
blocks	NULL
Tpl-2-induced	NULL
NFAT	NULL
activation	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
Raf1S8621A	NULL
,	NULL
a	NULL
dominant	NULL
negative	NULL
mutant	NULL
of	NULL
Rafl	NULL
,	NULL
which	NULL
inhibits	NULL
the	NULL
Tpl-2-	NULL
and	NULL
v-Ha-ras-induced	NULL
activation	NULL
of	NULL
the	NULL
MAPK	NULL
(	NULL
Patriotis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
,	NULL
also	NULL
inhibits	NULL
the	NULL
Tpl-2-induced	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
and	NULL
NFAT	NULL
promoters	NULL
(	NULL
Figure	NULL
1	NULL
and	NULL
4	NULL
)	NULL
.	NULL

However	NULL
,	NULL
Raf1	NULL
Y340D	NULL
,	NULL
an	NULL
active	NULL
form	NULL
of	NULL
Raf	NULL
,	NULL
activated	NULL
the	NULL
MAPK	NULL
pathway	NULL
(	NULL
Patriotis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
but	NULL
failed	NULL
to	NULL
activate	NULL
NFAT	NULL
and	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
Figure	NULL
2	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
Rafl	NULL
is	NULL
required	NULL
but	NULL
it	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
drive	NULL
the	NULL
NFAT	NULL
or	NULL
the	NULL
IL-2	NULL
promoters	NULL
,	NULL
indicating	NULL
that	NULL
Ras	NULL
needs	NULL
additional	NULL
effectors	NULL
that	NULL
activate	NULL
calcineurin	NULL
to	NULL
initiate	NULL
transcription	NULL
from	NULL
these	NULL
promoters	NULL
.	NULL

Although	NULL
CsA	NULL
fully	NULL
blocks	NULL
the	NULL
activation	NULL
of	NULL
NFAT	NULL
by	NULL
v-Ha-ras	NULL
it	NULL
only	NULL
partially	NULL
inhibits	NULL
the	NULL
activation	NULL
of	NULL
NFAT	NULL
by	NULL
Tpl-2	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
Tpl-2	NULL
may	NULL
activate	NULL
NFAT	NULL
via	NULL
Ras-dependent	NULL
signals	NULL
that	NULL
activate	NULL
calcineurin	NULL
and	NULL
through	NULL
Ras-independent	NULL
signals	NULL
that	NULL
function	NULL
downstream	NULL
of	NULL
calcineurin	NULL
.	NULL

Both	NULL
Bel-2	NULL
and	NULL
Bcl-X	NULL
,	NULL
fully	NULL
block	NULL
the	NULL
Tpl-2-mediated	NULL
NFAT	NULL
activation	NULL
.	NULL

We	NULL
therefore	NULL
conclude	NULL
that	NULL
Bcl-2	NULL
and	NULL
Bel-X	NULL
;	NULL
,	NULL
block	NULL
both	NULL
NFAT	NULL
activation	NULL
pathways	NULL
triggered	NULL
by	NULL
Tpl-2	NULL
and	NULL
not	NULL
only	NULL
the	NULL
activation	NULL
of	NULL
calcineurin	NULL
as	NULL
originally	NULL
suggested	NULL
(	NULL
Shibasaki	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Bcl-2	NULL
binds	NULL
the	NULL
catalytic	NULL
domain	NULL
of	NULL
calcineurin	NULL
through	NULL
its	NULL
BH4	NULL
domain	NULL
,	NULL
suggesting	NULL
that	NULL
it	NULL
may	NULL
also	NULL
bind	NULL
a	NULL
related	NULL
phosphatase	NULL
that	NULL
dephosphorylates	NULL
NFAT	NULL
and	NULL
is	NULL
CsA-resistant	NULL
.	NULL

The	NULL
BH4	NULL
domains	NULL
of	NULL
Bcel-2	NULL
and	NULL
Bel-	NULL
X	NULL
;	NULL
share	NULL
high	NULL
homology	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
BH4	NULL
domain	NULL
of	NULL
Mcl-1	NULL
which	NULL
is	NULL
more	NULL
distant	NULL
(	NULL
Sato	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
Bel-	NULL
X	NULL
,	NULL
and	NULL
Mcl-1	NULL
may	NULL
differ	NULL
in	NULL
their	NULL
ability	NULL
to	NULL
bind	NULL
the	NULL
catalytic	NULL
domain	NULL
of	NULL
calcineurin	NULL
.	NULL

The	NULL
calcineurin-independent	NULL
pathway	NULL
of	NULL
NFAT	NULL
activation	NULL
may	NULL
be	NULL
the	NULL
same	NULL
as	NULL
the	NULL
one	NULL
originally	NULL
proposed	NULL
by	NULL
(	NULL
Ghosh	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

2615	NULL
Tpl-2	NULL
activates	NULL
NFAT	NULL
and	NULL
NF-xB	NULL
C	NULL
Tsatsanis	NULL
et	NULL
al	NULL
2616	NULL
Experiments	NULL
presented	NULL
in	NULL
this	NULL
report	NULL
revealed	NULL
that	NULL
the	NULL
Tpl-2-mediated	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
also	NULL
depends	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
NF-xB	NULL
,	NULL
which	NULL
is	NULL
mediated	NULL
by	NULL
a	NULL
MEK	NULL
1	NULL
dependent	NULL
mechanism	NULL
.	NULL

Although	NULL
there	NULL
is	NULL
no	NULL
published	NULL
direct	NULL
evidence	NULL
to	NULL
date	NULL
that	NULL
MEK	NULL
1	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
NF-xB	NULL
,	NULL
recent	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
Rafl	NULL
,	NULL
the	NULL
activator	NULL
of	NULL
MEK	NULL
1	NULL
,	NULL
activates	NULL
NF-kB	NULL
perhaps	NULL
by	NULL
contributing	NULL
to	NULL
the	NULL
phosphorylation	NULL
and	NULL
proteolytic	NULL
degradation	NULL
of	NULL
Ix-Ba	NULL
«	NULL
(	NULL
Lee	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

The	NULL
investigation	NULL
of	NULL
the	NULL
role	NULL
of	NULL
Tpl-2	NULL
in	NULL
NF-xB	NULL
activation	NULL
was	NULL
triggered	NULL
by	NULL
the	NULL
surprizing	NULL
finding	NULL
that	NULL
inhibition	NULL
of	NULL
MEK1	NULL
and	NULL
MEK2	NULL
blocked	NULL
the	NULL
Tpl-2-induced	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
but	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
Tpl-2-mediated	NULL
activation	NULL
of	NULL
the	NULL
NFAT-driven	NULL
minimal	NULL
promoter	NULL
.	NULL

Since	NULL
the	NULL
activation	NULL
of	NULL
NFAT	NULL
depends	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
MAPK	NULL
pathway	NULL
this	NULL
finding	NULL
suggested	NULL
that	NULL
the	NULL
Tpl-2-mediated	NULL
activation	NULL
of	NULL
the	NULL
MAPK	NULL
is	NULL
MEK	NULL
1l-independent	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
it	NULL
suggested	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
Tpl-2	NULL
depends	NULL
on	NULL
the	NULL
MEK-dependent	NULL
activation	NULL
of	NULL
another	NULL
obligatory	NULL
pathway	NULL
.	NULL

The	NULL
data	NULL
presented	NULL
in	NULL
this	NULL
report	NULL
confirmed	NULL
both	NULL
hypothesis	NULL
and	NULL
demonstrated	NULL
that	NULL
the	NULL
MEK-dependent	NULL
pathway	NULL
that	NULL
is	NULL
activated	NULL
by	NULL
Tpl-2	NULL
and	NULL
contributes	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
is	NULL
the	NULL
NF-xB	NULL
activation	NULL
pathway	NULL
.	NULL

The	NULL
MEK	NULL
-dependence	NULL
of	NULL
the	NULL
Tpl-2-mediated	NULL
activation	NULL
of	NULL
the	NULL
MAPK	NULL
pathway	NULL
was	NULL
examined	NULL
in	NULL
transiently	NULL
transfected	NULL
COS-1	NULL
cells	NULL
.	NULL

The	NULL
Tpl-2-mediated	NULL
activation	NULL
of	NULL
the	NULL
MAPK	NULL
ERK	NULL
1	NULL
in	NULL
these	NULL
cells	NULL
was	NULL
mainly	NULL
MEK	NULL
1-independent	NULL
.	NULL

However	NULL
,	NULL
since	NULL
Tpl-2	NULL
phosphorylates	NULL
MEK1	NULL
in	NULL
vitro	NULL
(	NULL
Salmeron	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
,	NULL
the	NULL
Tpl-2-induced	NULL
MAPK	NULL
activation	NULL
may	NULL
be	NULL
transduced	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
via	NULL
MEK1	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
NF-xB	NULL
by	NULL
Tpl-2	NULL
was	NULL
not	NULL
surprizing	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
Tpl-2	NULL
kinase	NULL
domain	NULL
suggests	NULL
that	NULL
Tpl-2	NULL
is	NULL
a	NULL
member	NULL
of	NULL
the	NULL
family	NULL
of	NULL
MAP3Kinases	NULL
that	NULL
includes	NULL
MEKK1	NULL
(	NULL
Patriotis	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Ichijo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
,	NULL
Malinin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Earlier	NULL
studies	NULL
had	NULL
shown	NULL
that	NULL
MEKK1	NULL
and	NULL
the	NULL
related	NULL
NF-xB-inducing	NULL
kinase	NULL
(	NULL
NIK	NULL
)	NULL
associate	NULL
with	NULL
and	NULL
activate	NULL
the	NULL
large	NULL
molecular	NULL
weight	NULL
complex	NULL
that	NULL
phosphorylates	NULL
Ix-B	NULL
(	NULL
Lee	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
,	NULL
DiDonato	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
,	NULL
Mercurio	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
,	NULL
Zandi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

More	NULL
recent	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
indeed	NULL
MEKK1	NULL
as	NULL
well	NULL
as	NULL
NIK	NULL
phosphorylate	NULL
and	NULL
activate	NULL
the	NULL
Ix-B	NULL
kinases	NULL
IKK	NULL
«	NULL
and	NULL
IKKB	NULL
(	NULL
Lee	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Karin	NULL
and	NULL
Delhase	NULL
,	NULL
1998	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
these	NULL
observations	NULL
and	NULL
our	NULL
data	NULL
we	NULL
suggest	NULL
that	NULL
Tpl-2	NULL
may	NULL
also	NULL
phosphorylate	NULL
the	NULL
Ix-B	NULL
kinases	NULL
.	NULL

The	NULL
multiplicity	NULL
of	NULL
kinases	NULL
that	NULL
may	NULL
be	NULL
able	NULL
to	NULL
activate	NULL
the	NULL
Ix-B	NULL
kinases	NULL
suggests	NULL
that	NULL
each	NULL
of	NULL
them	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
transduction	NULL
of	NULL
some	NULL
but	NULL
not	NULL
all	NULL
NF-kB	NULL
activation	NULL
signals	NULL
.	NULL

Since	NULL
these	NULL
kinases	NULL
are	NULL
multifunctional	NULL
in	NULL
that	NULL
Tpl-2	NULL
also	NULL
activates	NULL
both	NULL
the	NULL
MAPK	NULL
and	NULL
the	NULL
SAPK	NULL
pathways	NULL
(	NULL
Ceci	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
;	NULL
Patriotis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Salmeron	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
,	NULL
MEKK1	NULL
activates	NULL
the	NULL
SAPK	NULL
pathway	NULL
(	NULL
Yan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
and	NULL
NIK	NULL
activates	NULL
neither	NULL
,	NULL
their	NULL
selective	NULL
utilization	NULL
by	NULL
different	NULL
signals	NULL
can	NULL
provide	NULL
significant	NULL
specificity	NULL
to	NULL
the	NULL
cellular	NULL
response	NULL
.	NULL

If	NULL
Tpl-2	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
phosphorylation	NULL
of	NULL
the	NULL
Ix-B	NULL
kinases	NULL
,	NULL
the	NULL
role	NULL
of	NULL
MEKI/MEK2	NULL
suggested	NULL
by	NULL
our	NULL
findings	NULL
is	NULL
not	NULL
currently	NULL
clear	NULL
.	NULL

One	NULL
possibility	NULL
is	NULL
that	NULL
MEK1/MEK2	NULL
plays	NULL
an	NULL
intermediate	NULL
role	NULL
in	NULL
this	NULL
process	NULL
and	NULL
provides	NULL
a	NULL
complimentary	NULL
signal	NULL
.	NULL

Overall	NULL
,	NULL
the	NULL
data	NULL
presented	NULL
in	NULL
this	NULL
report	NULL
show	NULL
that	NULL
Tpl-2	NULL
,	NULL
a	NULL
proto-oncogene	NULL
associated	NULL
with	NULL
tumor	NULL
progression	NULL
in	NULL
retrovirus	NULL
induced	NULL
rodent	NULL
T-cell	NULL
lymphomas	NULL
activates	NULL
multiple	NULL
signaling	NULL
pathways	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
NFAT	NULL
and	NULL
NF-xB	NULL
and	NULL
the	NULL
induction	NULL
of	NULL
IL-2	NULL
in	NULL
T	NULL
cells	NULL
through	NULL
these	NULL
pathways	NULL
suggests	NULL
that	NULL
Tpl-2	NULL
may	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
defines	NULL
a	NULL
potential	NULL
molecular	NULL
mechanism	NULL
that	NULL
may	NULL
contribute	NULL
to	NULL
its	NULL
oncogenic	NULL
potential	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Cells	NULL
and	NULL
cell	NULL
culture	NULL
EL4	NULL
cells	NULL
(	NULL
EL4.IL-2	NULL
,	NULL
obtained	NULL
from	NULL
ATCC	NULL
)	NULL
were	NULL
cultured	NULL
at	NULL
37°C	NULL
and	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
in	NULL
DMEM	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
horse	NULL
serum	NULL
(	NULL
HS	NULL
)	NULL
and	NULL
Penicillin	NULL
(	NULL
50	NULL
IU/ml	NULL
!	NULL
)	NULL

,	NULL
Streptomycin	NULL
(	NULL
50	NULL
ug/ml	NULL
)	NULL
and	NULL
Kanamycin	NULL
(	NULL
100	NULL
ug/ml	NULL
)	NULL
(	NULL
PSK	NULL
)	NULL
.	NULL

Jurkat	NULL
cells	NULL
(	NULL
clone	NULL
6.1	NULL
from	NULL
ATCC	NULL
)	NULL
were	NULL
also	NULL
cultured	NULL
at	NULL
37°C	NULL
and	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
in	NULL
RPMI-1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
FBS	NULL
)	NULL
and	NULL
PSK	NULL
.	NULL

EL4	NULL
and	NULL
Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
(	NULL
10	NULL
nm	NULL
)	NULL
and	NULL
ionomycin	NULL
(	NULL
2	NULL
nM	NULL
)	NULL
for	NULL
8	NULL
h	NULL
for	NULL
IL-2	NULL
or	NULL
NFAT	NULL
induction	NULL
.	NULL

Cyclosporin	NULL
A	NULL
,	NULL
an	NULL
immunosuppressive	NULL
agent	NULL
that	NULL
inhibits	NULL
calcineurin	NULL
,	NULL
was	NULL
added	NULL
in	NULL
some	NULL
cultures	NULL
at	NULL
100	NULL
ng/ml	NULL
,	NULL
PDO098059	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
MEK1	NULL
and	NULL
MEK2	NULL
provided	NULL
by	NULL
Dr	NULL
A	NULL
Saltiel	NULL
(	NULL
Parke	NULL
Davis	NULL
Pharmaceuticals	NULL
)	NULL
was	NULL
also	NULL
added	NULL
at	NULL
50	NULL
um	NULL
where	NULL
indicated	NULL
.	NULL

Plasmids	NULL
The	NULL
reporter	NULL
plasmid	NULL
IL-2/CAT	NULL
(	NULL
15deltacxCAT	NULL
)	NULL
containing	NULL
the	NULL
initiation	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
and	NULL
326	NULL
bps	NULL
of	NULL
upstream	NULL
sequences	NULL
(	NULL
Durand	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
was	NULL
provided	NULL
by	NULL
Dr	NULL
G	NULL
Crabtree	NULL
(	NULL
Stanford	NULL
University	NULL
Med	NULL
.	NULL

School	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

The	NULL
reporter	NULL
construct	NULL
pSPNFAT/CAT	NULL
,	NULL
containing	NULL
three	NULL
NFAT	NULL
binding	NULL
sites	NULL
(	NULL
AGAAAGGAG-GAAAAACTGTTTCATACAGAAGGCGTT	NULL
)	NULL
-	NULL
upstream	NULL
of	NULL
the	NULL
SV40	NULL
minimal	NULL
promoter	NULL
(	NULL
Thompson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
was	NULL
provided	NULL
by	NULL
Dr	NULL
C	NULL
Thompson	NULL
(	NULL
University	NULL
of	NULL
Chicago	NULL
)	NULL
.	NULL

The	NULL
mutant	NULL
IL-2/CAT	NULL
constructs	NULL
were	NULL
generated	NULL
by	NULL
overlap	NULL
extension	NULL
PCR	NULL
using	NULL
oligonucleotides	NULL
containing	NULL
mutations	NULL
in	NULL
the	NULL
following	NULL
sites	NULL
:	NULL
NFAT	NULL
site	NULL
at	NULL
-280	NULL
(	NULL
AGGAGGAA	NULL
changed	NULL
to	NULL
ACGTCCTA	NULL
)	NULL
;	NULL
NF-xB	NULL
site	NULL
at	NULL
-205	NULL
(	NULL
AAGAGGGATTT	NULL
changed	NULL
to	NULL
AGGAITTGATGT	NULL
)	NULL
;	NULL
and	NULL
NFAT-like	NULL
CD28RE	NULL
site	NULL
at	NULL
-160	NULL
(	NULL
GGTTTAAAGA	NULL
changed	NULL
to	NULL
GCTCTTACCA	NULL
)	NULL
.	NULL

The	NULL
wild-type	NULL
Ix-Ba	NULL
expression	NULL
construct	NULL
and	NULL
the	NULL
reporter	NULL
plasmid	NULL
NF-	NULL
«	NULL
xB/CAT	NULL
which	NULL
consists	NULL
of	NULL
six	NULL
NF-xB	NULL
binding	NULL
sites	NULL
upstream	NULL
the	NULL
thymidine	NULL
kinase	NULL
(	NULL
TK	NULL
)	NULL
minimal	NULL
promoter	NULL
and	NULL
a	NULL
CAT	NULL
reporter	NULL
gene	NULL
,	NULL
were	NULL
provided	NULL
by	NULL
Dr	NULL
J	NULL
Caamano	NULL
(	NULL
Bristol	NULL
Myers	NULL
Squibb	NULL
)	NULL
.	NULL

The	NULL
constitutively	NULL
active	NULL
mutant	NULL
calcineurin	NULL
pSRaACnA	NULL
(	NULL
Frantz	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
was	NULL
provided	NULL
by	NULL
Dr	NULL
E	NULL
O'Neill	NULL
(	NULL
Merck	NULL
Sharp	NULL
and	NULL
Dohme	NULL
,	NULL
Rahway	NULL
,	NULL
NJ	NULL
,	NULL
USA	NULL
)	NULL
,	NULL
NFAT	NULL
,	NULL
(	NULL
pSH102	NULL
)	NULL
and	NULL
the	NULL
dominant	NULL
negative	NULL
ANFAT	NULL
.	NULL

(	NULL
pSH102CA418	NULL
)	NULL
constructs	NULL
(	NULL
Northrop	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
were	NULL
provided	NULL
by	NULL
Dr	NULL
G	NULL
Crabtree	NULL
.	NULL

The	NULL
dominant	NULL
negative	NULL
MEK1	NULL
-	NULL
mutant	NULL
(	NULL
MEK	NULL
(	NULL
Pang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
was	NULL
provided	NULL
by	NULL
Dr	NULL
A	NULL
Saltiel	NULL
(	NULL
Parke	NULL
Davis	NULL
Pharmaceuticals	NULL
,	NULL
Ann	NULL
Arbor	NULL
,	NULL
MI	NULL
,	NULL
USA	NULL
)	NULL
,	NULL
the	NULL
wild-type	NULL
and	NULL
the	NULL
kinase	NULL
inactive	NULL
SEK-1	NULL
mutant	NULL
(	NULL
SEK1	NULL
K	NULL
299	NULL
R	NULL
)	NULL
(	NULL
Sanchez	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
were	NULL
provided	NULL
by	NULL
Dr	NULL
J	NULL
Chernoff	NULL
(	NULL
Fox	NULL
Chase	NULL
Cancer	NULL
Center	NULL
)	NULL
.	NULL

Activated	NULL
Rafl	NULL
(	NULL
Raf1Y340D	NULL
)	NULL
and	NULL
the	NULL
dominant	NULL
inhibitory	NULL
Rafl	NULL
mutant	NULL
(	NULL
RaflS621A	NULL
)	NULL
were	NULL
provided	NULL
by	NULL
Dr	NULL
D	NULL
Morrison	NULL
(	NULL
Morrison	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
(	NULL
NCI	NULL
,	NULL
FCRDC	NULL
,	NULL
Freder-ick	NULL
,	NULL
MD	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
calmodulin	NULL
modulating	NULL
ligand	NULL
(	NULL
CAML	NULL
)	NULL
expression	NULL
plasmid	NULL
(	NULL
Bram	NULL
and	NULL
Crabtree	NULL
,	NULL
1994	NULL
)	NULL
was	NULL
provided	NULL
by	NULL
Dr	NULL
R	NULL
Bram	NULL
(	NULL
St.	NULL
Jude	NULL
's	NULL
Children	NULL
's	NULL
Hospital	NULL
,	NULL
Memphis	NULL
,	NULL
TN	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

The	NULL
Bel-2	NULL
and	NULL
Bcl-X	NULL
;	NULL
,	NULL
expression	NULL
plasmids	NULL
were	NULL
provided	NULL
by	NULL
Dr	NULL
S	NULL
Korsmeyer	NULL
(	NULL
Washington	NULL
University	NULL
)	NULL
and	NULL
the	NULL
Mcl-1	NULL
expression	NULL
plasmid	NULL
by	NULL
Dr	NULL
D	NULL
Craig	NULL
(	NULL
Dartmouth	NULL
University	NULL
)	NULL
.	NULL

IL-2	NULL
assays	NULL
IL-2	NULL
secretion	NULL
was	NULL
measured	NULL
in	NULL
supernatants	NULL
of	NULL
transiently	NULL
transfected	NULL
Jurkat	NULL
cells	NULL
collected	NULL
36	NULL
h	NULL
after	NULL
transfection	NULL
.	NULL

Human	NULL
IL-2	NULL
was	NULL
measured	NULL
by	NULL
quantitative	NULL
ELISA	NULL
assays	NULL
according	NULL
to	NULL
the	NULL
protocols	NULL
provided	NULL
by	NULL
the	NULL
manufacturers	NULL
of	NULL
the	NULL
IL-2	NULL
ELISA	NULL
kit	NULL
(	NULL
IL-2EASIA	NULL
)	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
IL-2	NULL
was	NULL
presented	NULL
in	NULL
pg/ml	NULL
.	NULL

Transient	NULL
transfections	NULL
and	NULL
chloramphenicol-acetyl-transferase	NULL
(	NULL
CAT	NULL
)	NULL
Assays	NULL
EL4	NULL
or	NULL
Jurkat	NULL
cells	NULL
(	NULL
10	NULL
)	NULL
were	NULL
transiently	NULL
transfected	NULL
by	NULL
electroporation	NULL
(	NULL
260	NULL
mV	NULL
,	NULL
940	NULL
uF	NULL
)	NULL
and	NULL
harvested	NULL
44	NULL
h	NULL
later	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
8	NULL
h	NULL
prior	NULL
to	NULL
harvesting	NULL
,	NULL
or	NULL
they	NULL
were	NULL
treated	NULL
with	NULL
CsA	NULL
or	NULL
PDO098059	NULL
24	NULL
h	NULL
prior	NULL
to	NULL
harvesting	NULL
,	NULL
where	NULL
indicated	NULL
.	NULL

Transfections	NULL
were	NULL
carried	NULL
out	NULL
using	NULL
8	NULL
ug	NULL
IL-2/CAT	NULL
,	NULL
5	NULL
ug	NULL
NF-xB/CAT	NULL
or	NULL
6	NULL
ug	NULL
pSPNFAT/CAT	NULL
reporter	NULL
constructs	NULL
in	NULL
combination	NULL
with	NULL
2.5	NULL
ug	NULL
of	NULL
each	NULL
expression	NULL
construct	NULL
(	NULL
5	NULL
ug	NULL
total	NULL
)	NULL
.	NULL

In	NULL
cases	NULL
where	NULL
one	NULL
expression	NULL
construct	NULL
was	NULL
used	NULL
2.5	NULL
ug	NULL
of	NULL
CMVS5	NULL
empty	NULL
vector	NULL
was	NULL
added	NULL
to	NULL
bring	NULL
the	NULL
total	NULL
amount	NULL
of	NULL
vector	NULL
DNA	NULL
containing	NULL
the	NULL
CMV	NULL
promoter	NULL
to	NULL
6	NULL
ug	NULL
per	NULL
transfection	NULL
including	NULL
1	NULL
mg	NULL
of	NULL
CMV-B-Galactosidase	NULL
(	NULL
CMV-B-Gal	NULL
)	NULL
plasmid	NULL
.	NULL

pBluescript	NULL
was	NULL
added	NULL
to	NULL
bring	NULL
the	NULL
total	NULL
amount	NULL
of	NULL
electroporated	NULL
DNA	NULL
to	NULL
20	NULL
ug	NULL
.	NULL

Beta	NULL
galactosidase	NULL
expression	NULL
was	NULL
measured	NULL
as	NULL
described	NULL
(	NULL
Bignon	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
and	NULL
samples	NULL
were	NULL
normalized	NULL
for	NULL
equal	NULL
levels	NULL
of	NULL
expression	NULL
.	NULL

Each	NULL
transfection	NULL
was	NULL
carried	NULL
out	NULL
in	NULL
quadruplicate	NULL
and	NULL
every	NULL
experiment	NULL
was	NULL
repeated	NULL
at	NULL
least	NULL
twice	NULL
.	NULL

Chloramphenicol	NULL
acetyl	NULL
transferase	NULL
(	NULL
CAT	NULL
)	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Zweidler	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

The	NULL
acetyl	NULL
transferase	NULL
reaction	NULL
was	NULL
carried	NULL
out	NULL
for	NULL
3	NULL
h.	NULL
The	NULL
acetylated	NULL
and	NULL
the	NULL
non-acetylated	NULL
forms	NULL
of	NULL
'*C-chloramphenicol	NULL
(	NULL
Amersham	NULL
)	NULL
were	NULL
separated	NULL
on	NULL
TLC	NULL
plates	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

Chloramphenicol	NULL
acetylation	NULL
was	NULL
quantitated	NULL
using	NULL
Fuji	NULL
phosphor-imager	NULL
and	NULL
Fuji	NULL
Mac-bas	NULL
V2.2	NULL
software	NULL
.	NULL

Immunoprecipitation	NULL
and	NULL
in-gel	NULL
kinase	NULL
assay	NULL
Cells	NULL
were	NULL
washed	NULL
with	NULL
ice-cold	NULL
PBS	NULL
and	NULL
they	NULL
were	NULL
lysed	NULL
on	NULL
ice	NULL
for	NULL
20	NULL
min	NULL
in	NULL
0.5	NULL
ml	NULL
of	NULL
an	NULL
NP-40	NULL
lysis	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
Tris	NULL
Cl	NULL
,	NULL
pH	NULL
8.0	NULL
,	NULL
137	NULL
mm	NULL
NaCl	NULL
,	NULL
0.5	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
Nonidet	NULL
P-40	NULL
,	NULL
10	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
glycerol	NULL
,	NULL
10	NULL
mM	NULL
NaF	NULL
,	NULL
1	NULL
mM	NULL
sodium	NULL
orthovana-date	NULL
,	NULL
1	NULL
mM	NULL
phenylmethyl-sulfonyl	NULL
fluoride	NULL
,	NULL
2.5	NULL
nM	NULL
okadaic	NULL
acid	NULL
(	NULL
Sigma	NULL
)	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
1x	NULL
complete	NULL
protease	NULL
inhibitors	NULL
(	NULL
Boehringer-Mannheim	NULL
)	NULL
)	NULL
.	NULL

The	NULL
cell	NULL
lysates	NULL
were	NULL
clarified	NULL
by	NULL
centrifugation	NULL
at	NULL
12000g	NULL
at	NULL
4°C	NULL
for	NULL
10	NULL
min	NULL
.	NULL

Subsequently	NULL
,	NULL
they	NULL
were	NULL
precleared	NULL
by	NULL
incubation	NULL
with	NULL
20	NULL
ul	NULL
of	NULL
a	NULL
50	NULL
%	NULL
suspension	NULL
of	NULL
protein	NULL
A/protein	NULL
G	NULL
(	NULL
1:1	NULL
)	NULL
-agarose	NULL
(	NULL
Gibco-BRL	NULL
)	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

Following	NULL
removal	NULL
of	NULL
the	NULL
agarose	NULL
beads	NULL
by	NULL
centrifugation	NULL
at	NULL
12000g	NULL
at	NULL
4°C	NULL
for	NULL
10	NULL
min	NULL
,	NULL
the	NULL
precleared	NULL
lysates	NULL
were	NULL
incubated	NULL
for	NULL
3	NULL
h	NULL
at	NULL
4°C	NULL
with	NULL
the	NULL
anti-HA	NULL
antibody	NULL
(	NULL
HAB11	NULL
)	NULL
(	NULL
1/250	NULL
dilution	NULL
)	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
40	NULL
ul	NULL
50	NULL
%	NULL
protein	NULL
A/protein	NULL
G	NULL
(	NULL
1:1	NULL
)	NULL
-agarose	NULL
.	NULL

The	NULL
immunoprecipi-tate/agarose	NULL
bead	NULL
complexes	NULL
were	NULL
collected	NULL
by	NULL
centrifugation	NULL
at	NULL
6000	NULL
g	NULL
for	NULL
2	NULL
min	NULL
at	NULL
4°C	NULL
,	NULL
and	NULL
they	NULL
were	NULL
washed	NULL
,	NULL
also	NULL
at	NULL
4°C	NULL
,	NULL
three	NULL
times	NULL
with	NULL
1	NULL
ml	NULL
lysis	NULL
buffer	NULL
and	NULL
twice	NULL
with	NULL
References	NULL
Bacuerle	NULL
PA	NULL
and	NULL
Baltimore	NULL
D.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
87	NULL
,	NULL
13-20	NULL
.	NULL

Ballester	NULL
A	NULL
,	NULL
Tobena	NULL
R	NULL
,	NULL
Lisbona	NULL
C	NULL
,	NULL
Calvo	NULL
V	NULL
and	NULL
Alemany	NULL
S.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
159	NULL
,	NULL
1613-1618	NULL
.	NULL

Beg	NULL
AA	NULL
and	NULL
Baldwin	NULL
Jr	NULL
AS	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
7	NULL
,	NULL
2064-2070	NULL
.	NULL

Bignon	NULL
C	NULL
,	NULL
Daniel	NULL
N	NULL
and	NULL
Djiane	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Biotechniques	NULL
,	NULL
15	NULL
,	NULL
243-246	NULL
.	NULL

Bram	NULL
RJ	NULL
and	NULL
Crabtree	NULL
GR	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
371	NULL
,	NULL
355-358	NULL
.	NULL

Tpl-2	NULL
activates	NULL
NFAT	NULL
and	NULL
NF-xB	NULL
C	NULL
Tsatsanis	NULL
et	NULL
al	NULL
1	NULL
ml	NULL
kinase	NULL
wash	NULL
buffer	NULL
containing	NULL
20	NULL
mm	NULL
HEPES	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
5	NULL
mM	NULL
MgCl	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
.	NULL

In-gel	NULL
kinase	NULL
assays	NULL
were	NULL
carried	NULL
out	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Patriotis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
pelleted	NULL
immuno-precipitates	NULL
were	NULL
electrophoresed	NULL
in	NULL
SDS	NULL
10	NULL
%	NULL
polyacryla-mide	NULL
gel	NULL
containing	NULL
myelin	NULL
basic	NULL
protein	NULL
(	NULL
MBP	NULL
,	NULL
Sigma	NULL
)	NULL
at	NULL
0.25	NULL
mg/ml	NULL
.	NULL

Subsequently	NULL
the	NULL
gel	NULL
was	NULL
treated	NULL
with	NULL
several	NULL
changes	NULL
of	NULL
50	NULL
mm	NULL
Tris	NULL
HCI	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
in	NULL
20	NULL
%	NULL
isopropyl	NULL
alcohol	NULL
for	NULL
1	NULL
h	NULL
and	NULL
for	NULL
an	NULL
additional	NULL
hour	NULL
with	NULL
50	NULL
mM	NULL
Tris	NULL
HCIl/6m	NULL
guanidinium	NULL
chloride/5	NULL
mM	NULL
beta	NULL
mercaptoethanol	NULL
.	NULL

The	NULL
gel	NULL
was	NULL
then	NULL
incubated	NULL
at	NULL
4°C	NULL
for	NULL
16	NULL
h	NULL
in	NULL
Tris	NULL
HCI	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
/0.04	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
Tween	NULL
20/5	NULL
mM	NULL
beta	NULL
mercaptoethanol	NULL
.	NULL

Subsequently	NULL
the	NULL
gel	NULL
was	NULL
equilibrated	NULL
for	NULL
30	NULL
min	NULL
in	NULL
kinase	NULL
buffer	NULL
(	NULL
40	NULL
mm	NULL
HEPES	NULL
,	NULL
pH	NULL
8.0/	NULL
2	NULL
mM	NULL
dithiothreitol/	NULL
0.1	NULL
mM	NULL
EGTA/	NULL
5	NULL
mM	NULL
magnesium	NULL
acetate	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
gel	NULL
was	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
in	NULL
kinase	NULL
buffer	NULL
containing	NULL
20	NULL
mM	NULL
ATP	NULL
and	NULL
150	NULL
Ci	NULL
[	NULL
y-	NULL
``	NULL
PJATP	NULL
(	NULL
Amersham	NULL
;	NULL
3000	NULL
Ci/mmol	NULL
)	NULL
.	NULL

The	NULL
unincorporated	NULL
ATP	NULL
was	NULL
removed	NULL
by	NULL
washing	NULL
for	NULL
2-2.5	NULL
h	NULL
with	NULL
several	NULL
changes	NULL
of	NULL
5	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
trichloroacetic	NULL
acid	NULL
1	NULL
%	NULL
(	NULL
w/	NULL
v	NULL
)	NULL
sodium	NULL
pyrophosphate	NULL
.	NULL

The	NULL
gel	NULL
was	NULL
then	NULL
dried	NULL
and	NULL
exposed	NULL
to	NULL
XAR	NULL
film	NULL
(	NULL
Kodak	NULL
)	NULL
.	NULL

Immunoblotting	NULL
SDS-PAGE	NULL
and	NULL
electroblotting	NULL
were	NULL
carried	NULL
out	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Patriotis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

The	NULL
antibodies	NULL
and	NULL
the	NULL
dilutions	NULL
at	NULL
which	NULL
they	NULL
were	NULL
used	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
anti-HA	NULL
tag	NULL
(	NULL
HA.11	NULL
,	NULL
BaBco	NULL
)	NULL
(	NULL
1/1000	NULL
dilution	NULL
)	NULL
,	NULL
anti-T'pl-2	NULL
(	NULL
PT492	NULL
rabbit	NULL
polyclonal	NULL
)	NULL
(	NULL
1/1000	NULL
dilution	NULL
)	NULL
,	NULL
anti-MEKI1	NULL
(	NULL
SC-219	NULL
,	NULL
Santa	NULL
Cruz	NULL
)	NULL
(	NULL
1/1000	NULL
dilution	NULL
)	NULL
.	NULL

Excess	NULL
antibody	NULL
was	NULL
removed	NULL
by	NULL
two	NULL
10	NULL
min	NULL
and	NULL
three	NULL
5	NULL
min	NULL
washes	NULL
in	NULL
PBS	NULL
containing	NULL
0.1	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
Tween-20	NULL
.	NULL

Antigen-bound	NULL
antibody	NULL
was	NULL
detected	NULL
by	NULL
a	NULL
60	NULL
min	NULL
room	NULL
temperature	NULL
incubation	NULL
in	NULL
a	NULL
1/5000	NULL
dilution	NULL
of	NULL
the	NULL
corresponding	NULL
secondary	NULL
antibody	NULL
conjugated	NULL
with	NULL
horseradish	NULL
peroxidase	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

The	NULL
unbound	NULL
secondary	NULL
antibody	NULL
was	NULL
removed	NULL
using	NULL
the	NULL
same	NULL
washing	NULL
procedure	NULL
we	NULL
used	NULL
to	NULL
remove	NULL
the	NULL
excess	NULL
primary	NULL
antibody	NULL
with	NULL
three	NULL
additional	NULL
10	NULL
min	NULL
washes	NULL
in	NULL
PBS	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
the	NULL
secondary	NULL
antibody	NULL
was	NULL
detected	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
ECL	NULL
,	NULL
Amersham	NULL
)	NULL
.	NULL

Immuno-blots	NULL
were	NULL
exposed	NULL
to	NULL
Reflection	NULL
NEF	NULL
film	NULL
(	NULL
NEN	NULL
,	NULL
DuPont	NULL
)	NULL
for	NULL
1-10	NULL
min	NULL
.	NULL

Acknowledgments	NULL
We	NULL
wish	NULL
to	NULL
thank	NULL
Dr	NULL
R	NULL
Brahm	NULL
,	NULL
Dr	NULL
J	NULL
Caamano	NULL
,	NULL
Dr	NULL
J	NULL
Chernoff	NULL
,	NULL
Dr	NULL
G	NULL
Crabtree	NULL
,	NULL
Dr	NULL
D	NULL
Morrison	NULL
,	NULL
Dr	NULL
E	NULL
O'Neill	NULL
,	NULL
Dr	NULL
A	NULL
Saltiel	NULL
and	NULL
Dr	NULL
C	NULL
Thompson	NULL
for	NULL
providing	NULL
reagents	NULL
used	NULL
in	NULL
the	NULL
course	NULL
of	NULL
this	NULL
work	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
methods	NULL
)	NULL
.	NULL

We	NULL
also	NULL
wish	NULL
to	NULL
thank	NULL
Dr	NULL
A	NULL
Makris	NULL
,	NULL
Dr	NULL
HL	NULL
Grimes	NULL
and	NULL
the	NULL
other	NULL
members	NULL
of	NULL
the	NULL
Tsichlis	NULL
laboratory	NULL
for	NULL
stimulating	NULL
discussions	NULL
and	NULL
Pat	NULL
Bateman	NULL
for	NULL
secretarial	NULL
assistance	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Public	NULL
Health	NULL
Service	NULL
grant	NULL
CA38047	NULL
.	NULL

Additional	NULL
support	NULL
was	NULL
provided	NULL
by	NULL
Public	NULL
Health	NULL
Service	NULL
grant	NULL
CAO06927	NULL
and	NULL
by	NULL
an	NULL
appropriation	NULL
from	NULL
the	NULL
Commonwealth	NULL
of	NULL
Pennsylvania	NULL
to	NULL
the	NULL
Fox	NULL
Chase	NULL
Cancer	NULL
Center	NULL
.	NULL

CP	NULL
is	NULL
a	NULL
special	NULL
fellow	NULL
of	NULL
the	NULL
Leukemia	NULL
Society	NULL
of	NULL
America	NULL
Inc.	NULL
Ceci	NULL
JD	NULL
,	NULL
Patriotis	NULL
CP	NULL
,	NULL
Tsatsanis	NULL
C	NULL
,	NULL
Makris	NULL
AM	NULL
,	NULL
Kovatch	NULL
R	NULL
,	NULL
Swing	NULL
DA	NULL
,	NULL
Jenkins	NULL
NA	NULL
,	NULL
Tsichlis	NULL
PN	NULL
and	NULL
Copeland	NULL
NG	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
11	NULL
,	NULL
688-700	NULL
.	NULL

Chen	NULL
Z	NULL
,	NULL
Hagler	NULL
J	NULL
,	NULL
Palombella	NULL
VJ	NULL
,	NULL
Melandri	NULL
F	NULL
,	NULL
Scherer	NULL
D	NULL
,	NULL
Ballard	NULL
D	NULL
and	NULL
Maniatis	NULL
T.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
9	NULL
,	NULL
1586-1597	NULL
.	NULL

Chow	NULL
CW	NULL
,	NULL
Rincon	NULL
M	NULL
,	NULL
Cavanagh	NULL
J	NULL
,	NULL
Dickens	NULL
M	NULL
and	NULL
Davis	NULL
RJ	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
278	NULL
,	NULL
1638-1641	NULL
.	NULL

2617	NULL
Tpl-2	NULL
activates	NULL
NFAT	NULL
and	NULL
NF-xB	NULL
C	NULL
Tsatsanis	NULL
et	NULL
al	NULL
2618	NULL
Clipstone	NULL
NA	NULL
and	NULL
Crabtree	NULL
GR	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
357	NULL
,	NULL
695	NULL
697	NULL
.	NULL

Clipstone	NULL
NA	NULL
,	NULL
Fiorentino	NULL
DF	NULL
and	NULL
Crabtree	NULL
GR	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
269	NULL
,	NULL
26431-26437	NULL
.	NULL

DiDonato	NULL
JA	NULL
,	NULL
Hayakawa	NULL
M	NULL
,	NULL
Rothwarf	NULL
DM	NULL
,	NULL
Zandi	NULL
E	NULL
and	NULL
Karin	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
388	NULL
,	NULL
519-521	NULL
.	NULL

Durand	NULL
DB	NULL
,	NULL
Shaw	NULL
JP	NULL
,	NULL
Bush	NULL
MR	NULL
,	NULL
Replogle	NULL
RE	NULL
,	NULL
Belagaje	NULL
R	NULL
and	NULL
Crabtree	NULL
GR	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
8	NULL
,	NULL
1715-1724	NULL
.	NULL

Erny	NULL
KM	NULL
,	NULL
Peli	NULL
J	NULL
,	NULL
Lambert	NULL
JF	NULL
,	NULL
Muller	NULL
V	NULL
and	NULL
Diggelmann	NULL
H.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
13	NULL
,	NULL
2015-2020	NULL
.	NULL

Frantz	NULL
B	NULL
,	NULL
Nordby	NULL
EC	NULL
,	NULL
Bren	NULL
G	NULL
,	NULL
Steffan	NULL
N	NULL
,	NULL
Paya	NULL
CV	NULL
,	NULL
Kincaid	NULL
RL	NULL
,	NULL
Tocci	NULL
MJ	NULL
,	NULL
O'Keefe	NULL
SJ	NULL
and	NULL
O'Neill	NULL
EA	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
13	NULL
,	NULL
861-870	NULL
.	NULL

Fruman	NULL
DA	NULL
,	NULL
Pai	NULL
SY	NULL
,	NULL
Burakoff	NULL
SJ	NULL
and	NULL
Bierer	NULL
BE	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
15	NULL
,	NULL
3857-3863	NULL
.	NULL

Fujita	NULL
T	NULL
,	NULL
Nolan	NULL
GP	NULL
,	NULL
Ghosh	NULL
S	NULL
and	NULL
Baltimore	NULL
D.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
6	NULL
,	NULL
775-787	NULL
.	NULL

Garrity	NULL
PA	NULL
,	NULL
Chen	NULL
D	NULL
,	NULL
Rothenberg	NULL
EV	NULL
and	NULL
Wold	NULL
BJ	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
14	NULL
,	NULL
2159-2169	NULL
.	NULL

Ghosh	NULL
P	NULL
,	NULL
Sica	NULL
A	NULL
,	NULL
Cippitelli	NULL
M	NULL
,	NULL
Subleski	NULL
J	NULL
,	NULL
Lahesmaa	NULL
R	NULL
,	NULL
Young	NULL
HA	NULL
and	NULL
Rice	NULL
NR	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
271	NULL
,	NULL
7700-7704	NULL
.	NULL

Ichijo	NULL
H	NULL
,	NULL
Nishida	NULL
E	NULL
,	NULL
Irie	NULL
K	NULL
,	NULL
ten	NULL
Dijke	NULL
P	NULL
,	NULL
Saitoh	NULL
M	NULL
,	NULL
Moriguchi	NULL
T	NULL
,	NULL
Takagi	NULL
M	NULL
,	NULL
Matsumoto	NULL
K	NULL
,	NULL
Miyazono	NULL
K	NULL
and	NULL
Gotoh	NULL
Y	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Science	NULL
,	NULL
275	NULL
,	NULL
90-94	NULL
.	NULL

Jain	NULL
J	NULL
,	NULL
Loh	NULL
C	NULL
and	NULL
Rao	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
7	NULL
,	NULL
333-342	NULL
.	NULL

Jain	NULL
J	NULL
,	NULL
McCaffrey	NULL
PG	NULL
,	NULL
Miner	NULL
Z	NULL
,	NULL
Kerppola	NULL
TK	NULL
,	NULL
Lambert	NULL
JN	NULL
,	NULL
Verdine	NULL
GL	NULL
,	NULL
Curran	NULL
T	NULL
and	NULL
Rao	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
365	NULL
,	NULL
352-355	NULL
.	NULL

Jain	NULL
J	NULL
,	NULL
McCaffrey	NULL
PG	NULL
,	NULL
Valge	NULL
AV	NULL
and	NULL
Rao	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
356	NULL
,	NULL
801-804	NULL
.	NULL

Karin	NULL
M	NULL
and	NULL
Delhase	NULL
M.	NULL
(	NULL
1998	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
95	NULL
,	NULL
9067-9069	NULL
.	NULL

Lee	NULL
FS	NULL
,	NULL
Hagler	NULL
J	NULL
,	NULL
Chen	NULL
ZS	NULL
and	NULL
Maniatis	NULL
T.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
88	NULL
,	NULL
213-222	NULL
.	NULL

Lee	NULL
FS	NULL
,	NULL
Peters	NULL
RT	NULL
,	NULL
Dang	NULL
LC	NULL
and	NULL
Maniatis	NULL
T.	NULL
(	NULL
1998	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
95	NULL
,	NULL
9319-9324	NULL
.	NULL

Linette	NULL
GP	NULL
,	NULL
Li	NULL
Y	NULL
,	NULL
Roth	NULL
K	NULL
and	NULL
Korsmeyer	NULL
SJ	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
93	NULL
,	NULL
9545-9552	NULL
.	NULL

Luo	NULL
C	NULL
,	NULL
Burgeon	NULL
E	NULL
,	NULL
Carew	NULL
JA	NULL
,	NULL
McCaffrey	NULL
PG	NULL
,	NULL
Badalian	NULL
TM	NULL
,	NULL
Lane	NULL
WS	NULL
,	NULL
Hogan	NULL
PG	NULL
and	NULL
Rao	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
16	NULL
,	NULL
3955-3966	NULL
.	NULL

Makris	NULL
A	NULL
,	NULL
Patriotis	NULL
C	NULL
,	NULL
Bear	NULL
,	NULL
SE	NULL
and	NULL
Tsichlis	NULL
PN	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
67	NULL
,	NULL
4283-4289	NULL
.	NULL

Malinin	NULL
NL	NULL
,	NULL
Boldin	NULL
MP	NULL
,	NULL
Kovalenko	NULL
AV	NULL
and	NULL
Wallach	NULL
D.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
385	NULL
,	NULL
540-544	NULL
.	NULL

Mercurio	NULL
F	NULL
,	NULL
Zhu	NULL
H	NULL
,	NULL
Murray	NULL
BW	NULL
,	NULL
Shevchenko	NULL
A	NULL
,	NULL
Bennet	NULL
BL	NULL
,	NULL
Li	NULL
J	NULL
,	NULL
Young	NULL
DB	NULL
,	NULL
Barbosa	NULL
M	NULL
,	NULL
Mann	NULL
M	NULL
,	NULL
Manning	NULL
A	NULL
and	NULL
Rao	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
278	NULL
,	NULL
818-819	NULL
.	NULL

Morrison	NULL
DK	NULL
,	NULL
Kaplan	NULL
DR	NULL
,	NULL
Escobedo	NULL
JA	NULL
,	NULL
Rapp	NULL
UR	NULL
,	NULL
Roberts	NULL
TM	NULL
and	NULL
Williams	NULL
LT.	NULL
(	NULL
1989	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
58	NULL
,	NULL
649-657	NULL
.	NULL

Northrop	NULL
JP	NULL
,	NULL
Ho	NULL
SN	NULL
,	NULL
Chen	NULL
L	NULL
,	NULL
Thomas	NULL
DJ	NULL
,	NULL
Timmerman	NULL
LA	NULL
,	NULL
Nolan	NULL
GP	NULL
,	NULL
Admon	NULL
A	NULL
and	NULL
Crabtree	NULL
GR	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
369	NULL
,	NULL
497-502	NULL
.	NULL

Northrop	NULL
JP	NULL
,	NULL
Ullman	NULL
KS	NULL
and	NULL
Crabtree	NULL
GR	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

J.	NULL
Bio/	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
268	NULL
,	NULL
2917-2923	NULL
.	NULL

Pang	NULL
L	NULL
,	NULL
Zheng	NULL
CF	NULL
,	NULL
Guan	NULL
KL	NULL
and	NULL
Saltiel	NULL
AR	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Biochem	NULL
.	NULL

J.	NULL
,	NULL
307	NULL
,	NULL
513-519	NULL
.	NULL

Patriotis	NULL
C	NULL
,	NULL
Makris	NULL
A	NULL
,	NULL
Bear	NULL
SE	NULL
and	NULL
Tsichlis	NULL
PN	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
90	NULL
,	NULL
2251-2255	NULL
.	NULL

Patriotis	NULL
C	NULL
,	NULL
Makris	NULL
A	NULL
,	NULL
Chernoff	NULL
J	NULL
and	NULL
Tsichlis	NULL
PN	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
91	NULL
,	NULL
9755-9759	NULL
.	NULL

Rao	NULL
A	NULL
,	NULL
Luo	NULL
C	NULL
and	NULL
Hogan	NULL
PG	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

Ann	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
15	NULL
,	NULL
707-747	NULL
.	NULL

Rooney	NULL
JW	NULL
,	NULL
Sun	NULL
Y-L	NULL
,	NULL
Glimcher	NULL
LH	NULL
and	NULL
Hoey	NULL
T.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
15	NULL
,	NULL
6299-6310	NULL
.	NULL

Salmeron	NULL
A	NULL
,	NULL
Ahmad	NULL
TB	NULL
,	NULL
Carlile	NULL
GW	NULL
,	NULL
Pappin	NULL
D	NULL
,	NULL
Narsimhan	NULL
RP	NULL
and	NULL
Ley	NULL
SC	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
15	NULL
,	NULL
817-826	NULL
.	NULL

Sanchez	NULL
I	NULL
,	NULL
Hughes	NULL
RT	NULL
,	NULL
Mayer	NULL
BJ	NULL
,	NULL
Yee	NULL
K	NULL
,	NULL
Woodgett	NULL
JR	NULL
,	NULL
Avruch	NULL
J	NULL
,	NULL
Kyriakis	NULL
JM	NULL
and	NULL
Zon	NULL
LI	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
372	NULL
,	NULL
794-798	NULL
.	NULL

Sato	NULL
T	NULL
,	NULL
Hanada	NULL
M	NULL
,	NULL
Bordug	NULL
S	NULL
,	NULL
Irie	NULL
S	NULL
,	NULL
Iwama	NULL
N	NULL
,	NULL
Boise	NULL
LH	NULL
,	NULL
Thompson	NULL
CB	NULL
,	NULL
Golemis	NULL
E	NULL
,	NULL
Fong	NULL
L	NULL
,	NULL
Wang	NULL
HG	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
91	NULL
,	NULL
9238-9242	NULL
.	NULL

Schreiber	NULL
SL	NULL
and	NULL
Crabtree	NULL
GR	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Immunology	NULL
Today	NULL
,	NULL
13	NULL
,	NULL
136-142	NULL
.	NULL

Shibasaki	NULL
F	NULL
,	NULL
Kondo	NULL
E	NULL
,	NULL
Akagi	NULL
T	NULL
and	NULL
McKeon	NULL
F.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
386	NULL
,	NULL
728-731	NULL
.	NULL

Shibasaki	NULL
F	NULL
,	NULL
Price	NULL
ER	NULL
,	NULL
Milan	NULL
D	NULL
and	NULL
McKeon	NULL
F.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
382	NULL
,	NULL
370-373	NULL
.	NULL

Simeonidis	NULL
S	NULL
,	NULL
Liang	NULL
S	NULL
,	NULL
Chen	NULL
G	NULL
and	NULL
Thanos	NULL
D.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
94	NULL
,	NULL
14372-14377	NULL
.	NULL

Su	NULL
B	NULL
,	NULL
Jacinto	NULL
E	NULL
,	NULL
Hibi	NULL
M	NULL
,	NULL
Kallunki	NULL
T	NULL
,	NULL
Karin	NULL
M	NULL
and	NULL
Ben-Neriah	NULL
Y	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
77	NULL
,	NULL
727-736	NULL
.	NULL

Thanos	NULL
D	NULL
and	NULL
Maniatis	NULL
T.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
80	NULL
,	NULL
529-532	NULL
.	NULL

Thompson	NULL
CB	NULL
,	NULL
Wang	NULL
CY	NULL
,	NULL
Ho	NULL
IC	NULL
,	NULL
Bohjanen	NULL
PR	NULL
,	NULL
Petryniak	NULL
B	NULL
,	NULL
June	NULL
CH	NULL
,	NULL
Miesfeldt	NULL
S	NULL
,	NULL
Zhang	NULL
L	NULL
,	NULL
Nabel	NULL
GJ	NULL
,	NULL
Karpinski	NULL
B	NULL
and	NULL
Leiden	NULL
JM	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
12	NULL
,	NULL
1043-1053	NULL
.	NULL

Tsatsanis	NULL
C	NULL
,	NULL
Patriotis	NULL
P	NULL
,	NULL
Bear	NULL
SE	NULL
and	NULL
Tsichlis	NULL
PN	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
95	NULL
,	NULL
3827-3832	NULL
.	NULL

Yan	NULL
M	NULL
,	NULL
Dai	NULL
T.	NULL
,	NULL
Deak	NULL
JC	NULL
,	NULL
Kyriakis	NULL
JM	NULL
,	NULL
Zon	NULL
LI	NULL
,	NULL
Woodgett	NULL
JR	NULL
and	NULL
Templeton	NULL
DJ	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
372	NULL
,	NULL
798-800	NULL
.	NULL

Zandi	NULL
E	NULL
,	NULL
Rothwarf	NULL
DM	NULL
,	NULL
Delhase	NULL
M	NULL
,	NULL
Hayakawa	NULL
M	NULL
and	NULL
Karin	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
91	NULL
,	NULL
243-252	NULL
.	NULL

Zweidler	NULL
MP	NULL
,	NULL
Grimes	NULL
HL	NULL
,	NULL
Flubacher	NULL
MM	NULL
and	NULL
Tsichlis	NULL
PN	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
16	NULL
,	NULL
4024-4034	NULL
.	NULL

